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The opioid system, comprised mainly of the three opioid receptors (kappa, mu and delta)
and their endogenous neuropeptide ligands (dynorphin, endorphin and enkephalin, respectively),
mediates mood and reward. Activation of the mu opioid receptor is associated with positive
reward and euphoria, while activation of the kappa opioid receptor (KOR) has the opposite
effect. Activation of the KOR causes a decrease in dopamine levels in reward-related regions of
the brain, and can block the rewarding effects of various drugs of abuse, making it a potential
drug target for addictive diseases. KOR agonists are of particular interest for the treatment of
cocaine and other psychostimulant addictions, because there are currently no available
medications for these diseases. Studies in humans and animals, however, have shown that
activation of the KOR also causes negative side effects such as hallucinations, aversion and
sedation.
Several strategies are currently being employed to develop KOR agonists that block the
rewarding effects of drugs of abuse with fewer side effects, including KOR agonists with unique
pharmacology. The goal of the research presented here was to profile the signaling pathways
activated by KOR agonists and to investigate relationships between unique pharmacology and
animal models of KOR-mediated behaviors, in order to better understand how to target the KOR
for therapeutic use.
First, we quantified the effects of KOR agonists at both G-protein and b-arrestin-2
signaling pathways to compare to a variety of downstream effects, including sedation behavior.

We found that b-arrestin-2, but not G-protein, efficacy strongly correlated with sedation in mice.
We found that there was no apparent relationship between either G-protein or b-arrestin-2
signaling pathways with other investigated downstream signaling pathways, such as ERK1/2 and
mTOR, however. We also investigated the effects of KOR activation on protein-receptor
interactions, to identify other potential mediators of KOR effects.
Finally, we compared the effects of several unique KOR agonists on addiction-related
behaviors in mice. We found that nalfurafine, which is approved for human use in Japan, very
potent KOR agonist, was able to modulate the rewarding effects of cocaine at very low doses
that did not cause sedation or aversion. We also found that the commonly-used, full KOR agonist
U50,488 had a similar effect, suggesting that this “therapeutic window” could be a property of
the KOR system in general. Overall, this work suggests that KOR agonists at very low doses,
that show very little b-arrestin-2 signaling activity, may be able to modulate the rewarding
effects of cocaine while causing fewer negative side effects.
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CHAPTER 1. BACKGROUND AND GOALS
1.1 Opioid receptors mediate mood and reward, including addiction
With the rise of the “opiate epidemic” in recent years, addictions have come to the forefront
of the national conversation on health. Research has led to better understanding of some factors
that contribute to specific addictive diseases, leading to improved treatment options for some.
Addiction to opiate drugs like heroin, that target the mu opioid receptor, can be treated
effectively with medication-assisted therapy with drugs such as methadone and buprenorphine.6
Fewer effective options are available for those addicted to alcohol, however, and there are
currently no medication-assisted therapies for addiction to cocaine, methamphetamine and other
psychostimulants, which affect over 1 million people in the United States alone.1 Understanding
more about the different systems in the brain and body that are involved in addictive diseases,
such as the opioid system, can lead to better understanding of the disease, and better treatment
options.
Humans have used drugs that target opioid receptors for centuries for medicinal, and later
recreational, purposes, although the targets themselves weren’t discovered until the 1970’s.
Scientists used the displacement of radiolabeled naloxone in homogenized rodent brain tissue to
prove the existence of opioid receptors as specific and saturable binding sites for opioid drugs in
1973.2–4 It had long been hypothesized that there were several different opioid receptor subtypes,
based on the varying pharmacological properties of the different opioid drugs available to test in
human and animal models.5 Before they were definitively proven, two of these receptors were
named for the actions of different opioid drugs – the mu opioid receptor for its binding of
morphine and the kappa opioid receptor for its binding of the benzomorphan drug
ketocyclazocine.6 These opioid drugs with distinct pharmacological properties were eventually
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used to identify receptor subtypes. For example, a tritiated benzomorphan compound was used to
identify binding sites that were consistent with the pharmacological properties of this putative
kappa opioid receptor in guinea pig cerebellum.7 The delta opioid receptor was named later,
when it was found to be enriched in mouse vas deferens tissue.8 By the early 1990’s, scientists
had identified and cloned the three main opioid receptor subtypes.9–13
The three main opioid receptors (KOR, MOR and DOR) and their endogenous peptide
ligands (dynorphins, endorphins and enkephalins) are now recognized as crucial mediators of
mood and reward, as well as pain and other sensations. Genetic and pharmacological studies
have shown that the MOR system is necessary for the rewarding and euphoria-inducing
properties of many drugs of abuse, including MOR agonists like morphine and drugs of abuse
with different mechanisms of action, such as alcohol (reviewed in Darcq and Kieffer, 2018).14
The DOR system is thought to mediate mood, as DOR agonists are anxiolytic and cause antidepressant like behavior in animal models and DOR knock-out mice have increased anxiety and
depressive-like behavior.15 The KOR system, on the other hand, appears to negatively regulate
both mood and reward (Figure 1.1).

Figure 1.1. Opioid receptor systems differentially mediate mood and reward
2

1.2 The KOR system negatively regulates reward
In addition to causing the antinociceptive effects characteristic of most opioid agonists, KOR
agonists have been shown repeatedly to be aversive and dysphoric in both animal and human
studies. Early studies in rats found that the activation of KORs and MORs by small molecules
had opposing effects on dopamine release in reward-related regions of the brain; while MOR
agonists stimulated dopamine release, KOR agonists decreased dopamine release.16 Activation of
KORs by the endogenous peptide ligand dynorphin A (1-17) also led to a decrease in dopamine
release. 17 This is thought to be the mechanism through which the KOR system mediates
negative affect naturally. In animal models, for example, stressful experiences lead to negative
affect, as demonstrated by depressive and anxiety-like behaviors, and this process is mediated by
the KOR system.18,19 Both KOR and dynorphin expression appear to be upregulated following
administration of drugs such as morphine and cocaine in animal models,20–22 as well as after
cocaine overdose in humans,23 suggesting that the KOR system may also be involved in the
development of negative affective states in the addiction process.
Because of its anti-reward properties and role in addiction, many groups have investigated
the KOR as a potential therapeutic target for the treatment of addictive diseases. KOR agonists
have been shown to block the rewarding and reinforcing effects of several different drugs of
abuse in animal models such as self-administration and conditioned-place preference (reviewed
in Banks 2019).24 These drugs include cocaine, ethanol, and MOR agonists such as morphine.
Further, work from Yong Zhang has shown that activation of the KOR by dynorphin A (1-17)
can block the dopaminergic surge caused by cocaine in mice, suggesting a mechanism for this
reward blockade.17
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In models of stress-induced reinstatement of drug seeking, however, the KOR system appears
to potentiate reinstatement.19,25 Additionally, there have been studies demonstrating that KOR
agonists potentiate drug reward under certain circumstances in animal models.24 It is clear that
the KOR plays an important and complex role in the regulation of drug reward, and research is
ongoing to determine the best way to therapeutically target this receptor for the treatment of
addictive diseases. KOR agonists are particularly interesting for the treatment of cocaine and
other psychostimulant addictions, as there are currently no available medications for these
diseases.
1.3 Many KOR agonists have negative side effects in humans
Human studies have revealed negative side effects of KOR agonists that have hampered
drug development. In the 90’s and early 2000’s, the KOR-selective arylacetamide agonists
spiradoline (U69,066E) and enadoline were tested for analgesic efficacy in humans. Two studies
of enadoline in 1996 for post-operative and dental pain showed no effect of the KOR agonist on
analgesia overall.26,27 While the highest dose of enadoline tested did decrease some reports of
post-operative pain, the study had to be terminated early because of “neuropsychiatric events”,
including psychotomimetic effects and hallucinations.27 Studies of spiradoline similarly found
that this compound caused significant sedation in humans, as well as dysphoria, and that it could
not replace MOR analgesics because of these side effects (reviewed in Wadenburg 2003).28
Shortly after these clinical studies, scientists also identified the KOR as the target for the
main psychoactive compound in the plant Salvia divinorum.29,30 Leaves from this plant have
been used for centuries by the Mazatec people of Oaxaca, Mexico as part of their spiritual rituals
and practices, and more recently as a recreational hallucinogen in parts of Mexico and the United
States. The active compound, salvinorin A, was isolated in the 1980’s and its molecular target
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was identified as the kappa opioid receptor by Bryan Roth in the early 2000’s. 29 The potent
hallucinogenic properties of salvinorin A, as well as reports of sedation and dysphoria in Salvia
divinorum users, helped to confirm the effects of KOR agonist activity in humans, in addition to
providing a new scaffold for the development of unique kappa opioid compounds.31
Despite the adverse effects displayed by KOR agonists, there are some compounds
currently in clinical use that target the KOR. Nalmefene is currently approved to treat alcohol
addiction in Europe, and naltrexone is approved in the US for the treatment of opioid and alcohol
addiction. Nalmefene and naltrexone are both MOR antagonists that have recently been shown to
have partial KOR agonism for signaling through G-proteins.32–34 Neither drug appears to cause
the psychotomimetic, sedative or dysphoric side effects that are common to KOR agonists,
however, suggesting that their partial agonism or signaling profile at the KOR may be beneficial
for therapeutic development.
The only KOR-selective agonist that is used in humans is the compound nalfurafine,
approved in Japan to treat pruritus in 2009. It is extremely potent, with a daily oral dose of 2.5µg
for adults. While the reported KOR-mediated signaling properties of nalfurafine vary among
studies, likely due to differences in assays and cell lines, it has been shown to have full efficacy
at the KOR for almost all signaling pathways.35,36 Post-marketing studies have demonstrated
very few of the side effects expected with KOR agonism.37 Additional studies in animals have
examined the “therapeutic window” for nalfurafine dosing, between the doses that cause the
desired antinociceptive and antipruritic therapeutic effects and the doses that cause negative side
effects like sedation, and generally found that nalfurafine does not cause negative side effects at
therapeutic doses. Other KOR agonists such as salvinorin A and the well-characterized
arylacetamide agonist U50,488 tested in the same studies, however, caused negative side effects
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at the same doses needed for therapeutic effects in these antinociceptive and antipruritic
assays.35,38,39 Initial studies have demonstrated that nalfurafine modulates the rewarding effects
of drugs of abuse as well, although it is unclear how this effect compares with other KOR
agonists.
Finally, KOR antagonists have been tested preclinically for different therapeutic
indications including anti-depressant and anti-addictive properties.40 Limited human studies so
far have not demonstrated KOR blockade to be an effective treatment for depression or
addictions. 41,42 However the short-acting KOR antagonists that are currently under investigation
have also not shown any negative side effects.41,42
Together, the preclinical and clinical data suggest that KOR agonists with modified
pharmacological properties, such as partial agonists, or agonists like nalfurafine with unique
properties, could be potential therapeutics for treating addictive diseases, and particularly
cocaine and other stimulant addiction.43

1.4 KOR agonists activate multiple signaling pathways
Additionally, there is a large effort to make and test agonists that selectively activate only
certain pathways downstream of the KOR in order to confer therapeutic properties without
causing negative side effects. The KOR, along with the other opioid receptors, is an inhibitory Gprotein coupled receptor (GPCR). Upon receptor activation, heterotrimeric G-protein activation
leads to inhibition of cyclic AMP production and hyperpolarization via ion channel interactions.
Phosphorylation of the receptor also leads to the recruitment of b-arrestin-2, which leads to
receptor internalization. This receptor-arrestin complex also confers its own set of signaling
responses that may be independent of G-protein signaling (Figure 1.2). There have been recent
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discoveries of downstream signaling pathways of KORs that are both G-protein-dependent and
G-protein-independent (b-arrestin-dependent), including certain mitogen-activated protein
kinases (MAPKs) and, more recently, the mTOR signaling pathway (mammalian target of
rapamycin) (Figure 1.2).

Figure 1.2. G-protein coupled receptors signal through diverse pathways

Studies of genetic knockout animals have suggested that certain downstream effects in
vivo may require specific activation of these G-protein or b-arrestin signaling pathways.
Specifically, in arrestin-knockout mice, activation of the mu opioid receptor still caused
analgesia, but did not cause respiratory depression, suggesting that this side effect of MOR
agonists required b-arrestin signaling.44 This offers exciting possibilities for therapeutic
development, as agonists that activate only one pathway could be used to elicit only a specific
subset of downstream consequences, while excluding possible adverse effects (Figure 1.3).
These “biased” or “functionally-selective” MOR agonists are currently being developed for pain
relief based in part on studies from the Bohn laboratory and others reporting that G-protein
biased MOR agonists were anti-nociceptive, but did not induce respiratory depression, in rodent
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models.45–47 This hypothesis is still being tested in humans with the G-protein biased MOR
agonist TRV 130 (Oliceridine).48,49

Figure 1.3. Biased agonists may be able to selectively induce downstream effects

Efforts have also been made to characterize KOR agonist pharmacology and determine
which behaviors involve, or even require, G-protein or b-arrestin signaling (reviewed in Mores
2019).50 RB-64, among the first biased KOR agonists, is an analog of salvinorin A that
preferentially activates G-protein signaling over b-arrestin-2 signaling. In animal studies, this
compound was antinociceptive, however it did not cause the sedative effects caused by the
unbiased KOR agonists U50,488 and salvinorin A.51 Later studies of a novel series of G-protein
biased triazole compounds also suggested that b-arrestin signaling was necessary for the sedative
properties of KOR agonists, but not antipruritic or antinociceptive effects.52
There are also efforts to characterize additional novel KOR agonists, as well as
previously-described opioid compounds, for their G-protein versus arrestin bias at the kappa
opioid receptor. 53–55 Many of these compounds have been previously characterized in animal
8

models, and some even in humans, and understanding more about their pharmacology could help
improve understanding of the relationships between signaling pathways and behaviors
downstream of the KOR. These efforts, however, have highlighted some of the technical
difficulties in assigning an agonist the label of “biased”.
To measure ligand bias, the activities of a compound in two different signaling pathways
are compared. This requires selecting assays and endpoints for measuring activity, as well as a
reference agonist to designate “full” activity in each pathway, which can vary between studies.
Bias is most commonly quantified using the operational model of partial agonism first described
by Black and Leff in the 1980’s.56,57 By definition, all quantifications of ligand bias are specific
to the assays and reference agonists chosen.
In addition to these experimental details that can vary between labs, it has been shown
that agonist activity downstream of a receptor can vary depending on what cellular components
are available, meaning that measurements of ligand bias can vary between cell lines and tissues.
This makes it difficult to compare measurements of bias between studies, and also suggests that
in vitro measurements of ligand bias may not be indicative of signaling in disease-relevant tissue.
Despite these concerns, a recent 2017 study from the Bohn laboratory demonstrated that an in
vitro measurement of “Bias Factor” did in fact correlate significantly with the “therapeutic
window”, between antinociceptive and respiratory depression effects, in mice.46 While there are
many difficulties to measuring ligand bias, or understanding what signaling pathways are
activated in the disease-relevant tissue, this study demonstrated that these in vitro measurements
can be useful tools for guiding drug development efforts.
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1.5 Additional signaling pathways may be involved in opioid receptor signaling
In addition to investigating G-protein and b-arrestin signaling pathways, studies have
identified other signaling proteins that may be involved in opioid receptor effects. Several
proteins of the MAPK family, for example, have been implicated in KOR-mediated behavior.
The b-arrestin-dependent activation of the MAPK p38 has been shown to be important for
mediating the aversive effects of KOR agonists.58,59 Additionally, blockade of the KOR with
long acting antagonists has been shown to activate JNK (c-Jun N-terminal kinase) as well,
another MAPK protein.60 ERK1/2 (extracellular related kinases 1 and 2) proteins have been
shown to be phosphorylated after KOR activation by many different KOR agonists, and a study
with salvinorin A suggested that ERK1/2 activation is necessary for the blockade of dopamine
release by KOR agonists.61 An important study from the Bohn laboratory also demonstrated that
ERK1/2 phosphorylation downstream of the KOR could be independent of G-protein or barrestin activation, highlighting the importance of examining these additional signaling
pathways.62
A recent phosphoproteomic study compared signaling protein activation (via
phosphorylation patterns) in particular brain regions of mice treated with different KOR
agonists.39 This study identified that certain KOR agonists, at doses that caused aversion, led to
increased mTOR signaling compared to non-aversive KOR agonists. Follow-up studies indicated
that mTOR activation was necessary for KOR-mediated aversion, but not sedation, suggesting
that this signaling pathway may also be important to consider for the development of KOR
agonists with fewer side effects.36
New techniques in biochemistry and structural biology are also being developed to
investigate the molecular basis of opioid receptor signaling, particularly the differential
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activation of opioid receptors by biased ligands. For example, using nanobodies that selectively
bind the active conformation of the MOR, the Von Zastrow laboratory has identified differences
in the subcellular localization of active MORs after treatment of cells with the endogenous bendorphin peptide versus small molecule agonists.63 Strategies like these could help to identify
key relationships between drug action at the molecular level and the behavioral level, that could
in turn aid drive drug discovery efforts.

1.6 Research goals
Data from preclinical and clinical studies of KOR ligands suggest that modified
pharmacology, such as partial agonists or unique signaling pathway activation, could help lead to
KOR agonists with fewer side effects. Recent advances in GPCR research also suggest that
biased agonists, that selectively activate only certain pathways downstream of the receptor, could
also improve side effect profiles of different compounds. Here, we have explored several
different strategies to investigate the relationships between KOR signaling and behavior,
including exploring biased agonists, identifying other downstream signaling pathways and
testing compounds that have already proven to be safe in humans in preclinical mouse models of
cocaine reward.
In Chapter 3, 21 structurally-diverse KOR agonists were pharmacologically profiled for
both G-protein and b-arrestin-2 signaling, and their ligand bias in this context was quantified.
We then examined the relationships between these early G-protein and arrestin signaling
pathways and KOR-mediated sedation in mice, as measured by the rotarod assay.
In Chapter 4, we examined the ability of KOR agonists to activate additional signaling
pathways that have been more recently implicated in KOR-mediated behaviors, including
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ERK1/2 phosphorylation and mTOR activation. We also investigated novel pathways that may
be involved in KOR-signaling for future study.
Finally, in Chapter 5, we examined preclinical mouse models of KOR-mediated
behaviors using several different types of KOR agonists, including a G-protein biased agonist
and the clinically-utilized agonist nalfurafine. We compared the effective doses of different KOR
agonists for negative side effects, as well as models of cocaine reward and reinforcement.
Together, the goal of this work is to better understand the different pharmacological strategies
that could be used to develop KOR ligands for therapeutic use in the future.
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CHAPTER 2. MATERIALS AND METHODS
2.1. Chemical compounds
Dynorphin A(1-17) (YGGFLRIRPKLKWDNQ) was obtained from BACHEM. GR89686 (4[(3,4-Dichlorophenyl)acetyl]-3-(1-pyrrolidinylmethyl)-1-piperazinecarboxylic acid methyl ester
fumarate) was obtained from Tocris. Nor-Binaltorphimine was obtained from Abcam
(Cambridge, UK). Salvinorin A and Mesyl Salvinorin B were given by Dr. Tom Prisinzano
(University of Kansas). Nalmefene was obtained from Baker Norton Pharmaceuticals (Miami,
FL, USA). Nalfurafine was obtained from Adooq Bioscience (Irvine, CA, USA). N-substituted[N-[2-phenylethyl]-N-[2-(3-hydroxyphenyl)ethyl]-amines (where substitutions = N-butyl for
BPHA, cyclopropyl for HS666, methylcyclobutyl for MCBPHA and methylcyclopentyl for
MCPPHA) were synthesized by a contract research organization, WuXi Apptech (Shanghai,
China), using methods reported previously by the group of Schmidhammer.64 WMS 0610 (1-{4Benzyl-8 – pyrrolidine-1-yl-perhydroquinoxalinyl}-2-(3,4- dichlorophenyl)ethen one) and WMS
0611(2-(3,4-Dichlorophenyl)-1-(-8- pyrrolidine-1-yl-perhydroquinoxalinyl)- ethanone ) were
also synthesized by WuXi Apptech, using methods previously reported by the group of
Wunsch.65 For these synthesized compounds, mass spectrometric and NMR signals were in
agreement with previous publications. LY2444296 [(S)-3-fluoro-4-(4-((2-(3-fluorophenyl)
pyrrolidin-1-yl) methyl)phenoxy)benzamide] was also synthesized by WuXi, with a small
portion generously donated by Eli Lilly (Indianapolis, IN), which was used to confirm that the
WuXi synthesized compound was molecularly identical (as determined by reversed-phase highperformance liquid chromatography retention time). Remaining compounds were obtained from
Sigma (St. Louis, MO, USA). This includes U69,593[(-)-(5α,7α,8β)-N-Methyl-N-[7-(1pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide], U50,488 [trans-(±)-3,4-Dichloro-N-
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methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide], U62,066E [(±)-(5α,7α,8β)-3,4Dichloro-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]benzeneacetamide], and
ICI204448[(RS)-[3-[1-[[(3,4-Dichloro phenyl)acetyl]methylamino]-2-(1pyrrolidinyl)ethyl]phenoxy] acetic acid]. [3 H]U69,593, and [35 S]GTPγS were procured from
Perkin Elmer (Waltham, MA, USA). 3G1 and 3G2 were novel compounds synthesized by WuXi
Apptech, using methods adapted from those previously reported.64
2.2 In vitro signaling studies
2.2.1 b-arrestin-2 enzyme fragment complementation (ECF)
Experiments were conducted using the PathHunter Detection Kit obtained from DiscoveRx.
Cells stably expressing human kappa opioid receptors (PathHunter U2OS hOPRK1 β-arrestin-2
cell line, DiscoveRx, Fremont, CA, USA) were plated in 96- or 384-well plates. Cells were
stimulated with the compounds for 90 minutes at 37°C followed by incubation for 60 minutes in
the presence of galactosidase substrate, yielding chemiluminescent product. All concentrations
were tested in quadruplicate for each experiment, and had an N of 3 experiments total. Each 384well plate also had 32 additional replicates of 10µM U69,593 that were used for normalization.
Chemiluminescence was measured using a Synergy Neo microplate reader (BioTek, Winooski,
VT, USA). Antagonism assays were done in the same manner, in the presence of 300nM
U69,593.
2.2.2 [35S]GTPgS Binding with U2OS cell membranes
Membranes from U2OS cells (PathHunter U2OS hOPRK1) stably expressing human KORs were
used. Cells were scraped from tissue culture plates, homogenized with a Tissue Tearor
homogenizer in membrane buffer (10mM Tris-HCl, 100mM NaCl, and 1mM EDTA; pH 7.4),
and centrifuged at 20,000 g for 30 minutes at 4°C and frozen at -80°C until use. Prior to use, the
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pellets were resuspended in assay buffer (50mM Tris-HCl, 100mM NaCl, 5mM MgCl2, and
1mM EDTA; pH 7.4) and homogenized with a dounce homogenizer and 50 µg incubated with
0.1nM [35 S]GTPγS, 10nM GDP, and the appropriate concentration of agonist for 20 minutes at
30°C. All concentrations were tested in quadruplicate for each experiment, and had an N of 3
experiments total. Membranes with bound [35 S]GTPγS were collected on Whatman GF/B filter
paper (Brandel, Gaithersburg, MD, USA) utilizing a Brandel harvester. Bound [35 S]GTPγS was
quantified using a TriCarb-2900TR scintillation counter (Packard, Downers Grove, IL, USA)
following addition of 4 mL ReadySafe scintillation fluid (Beckman Coulter, Indianapolis, IN,
USA).
2.2.3 [35S]GTPgS Binding with mouse striatum tissue
Mice were euthanized by cervical dislocation, in a manner approved by The Rockefeller
University Institutional Animal Care and Use Committee. Ventral striatum tissue, corresponding
to the caudate putamen and nucleus accumbens regions, was removed immediately after sacrifice
and tissue was frozen in liquid nitrogen. Tissue samples were then stored at -80°C until further
use. Homogenization and assay protocol were adapted from Bohn, Zhou and Ho 201566 and
described below.
Striatum samples were homogenized in homogenization buffer (10mM Tris-HCl, pH 7.4,
100mM NaCl, 1mM EDTA, 1mM DTT added immediately prior to use) by a Tissue Tearor
homogenizor on ice, dounced in a dounce homogenizor and passed through a 26 gauge needle
for homogenization. The tissue was then centrifuged at 20,000 g for 30 minutes at 4°C, rinsed
with homogenization buffer and spun down again. Pellets were resuspended in assay buffer
(50mM Tris-HCl, pH 7.4, 100mM NaCl, 5mM MgCl2, 1mM EDTA, 1mM DTT added
immediately prior to use) and incubated with 0.1nM [35 S]GTPγS, 20 nM GDP, and the
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appropriate concentration of agonist for 1 hour at RT. All concentrations were tested in
quadruplicate. Membranes with bound [35 S]GTPγS were collected on Whatman GF/B filter
paper (Brandel, Gaithersburg, MD, USA) utilizing a Brandel harvester. Bound [35 S]GTPγS was
quantified using a TriCarb-2900TR scintillation counter (Packard, Downers Grove, IL, USA)
following addition of 4 mL ReadySafe scintillation fluid (Beckman Coulter, Indianapolis, IN,
USA).
2.2.4 In-cell western blots for ERK1/2 phosphorylation
HEK293 cells stably expressing a FLAG (DYKDDDDK) -tagged mouse KOR were plated in a
96-well plate and stimulated with compound for 5 minutes after 1 hour of serum starvation. All
concentrations were tested in triplicate. Cells were then prepared for immunofluorescent staining
with phosphorylated ERK1/2 (Phospho-p44/p42 MAPK, 1:100, Cell Signaling Technology,
Danvers, MA, USA) and GAPDH (GAPDH (0411), 1:100, Santa Cruz Biotechnology, Dallas, TX,
USA) primary antibodies, and near-infrared secondary antibodies (IRDye 680CW and IRDye
800CW, 1:500, LiCor Biosciences, Lincoln, NE, USA). Plates were imaged on the Li-Cor Odyssey
CLx Imaging System (LiCor Biosciences, Lincoln, NE, USA).
2.2.5 Western blots for Rps6 phosphorylation
U2OS cells (PathHunter U2OS hOPRK1) stably expressing human KORs were plated in a
96wwell plate and stimulated with compound for 1 hour after 14-16 hours of serum starvation. All
concentrations were run in triplicate. Cells were lysed with radioimmunoprecipitation (RIPA)
buffer (Thermo Fisher Scientific, Waltham, MA, USA). Samples were run on SDS PAGE gels,
and multiple gels trimmed and transferred to a single western blot (“multistrip” western blot).67
Blots were probed with phosphorylated Rps6 (P-S6 Ribosomal Protein (Ser240/244), 1:1000, Cell
Signaling Technology, Danvers, MA, USA) and GAPDH (GAPDH (0411), 1:1000, Santa Cruz
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Biotechnology, Dallas, TX, USA) primary antibodies, and near-infrared secondary antibodies
(IRDye 680CW and IRDye 800CW, 1:500, LiCor Biosciences, Lincoln, NE, USA). Blots were
imaged on the Li-Cor Odyssey CLx Imaging System (LiCor Biosciences, Lincoln, NE, USA) and
quantified using ImageJ (US National Institutes of Health, Bethesda, MD, USA).
2.2.6 LogRAi bias calculations
For all in vitro assays described here, data was normalized to the maximal response of 10µM
reference agonist U69,593 run at the same time. For [35S]GTPγS, β-arrestin-2, and ERK1/2
phosphorylation assays, dose response curves were determined using nonlinear regression in
Graphpad Prism 7 (GraphPad Software, San Diego, CA, USA) and EC50 and Emax values are
presented with standard error. LogRAi values were calculated as described in Ehlert, 200568 and
200869 [reviewed with other methods of bias analysis in Kenakin and Christopoulos 2013],70 as
the LogRAi = log(Emax/EC50). This value is analogous to the transduction factor calculated from
the operational model of partial agonism,57 as long as the slope factor of the dose-response curve
is 1.
In certain instances of very low maximal efficacy, competitive model analysis was
performed as described in Stahl et al., 2015 in Graphpad Prism 771. These cases are shown in
Figures 3.3 and 4.2. Normal dose-response data was used for each test compound, as well as
dose-response data from the test compound in competition with 300nM U69,593. The doseresponse curve of U69,593 was used for reference agonist data.
For each of these specific instances, the data was fit to the equations below. Here,
“Bottom” and “Top” refer to the minimum and maximum stimulation in the data set, as a
percentage of maximal U69,593 stimulation. This is the same units as the output, Y. The LogK
value is the dissociation constant of the ligand, either reference or test. LogR is the transduction
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coefficient of the reference ligand. 57 LogRA is the ratio of transduction coefficients of the test
ligand and the reference ligand. In these equations, X is the concentration of the test ligand,
while A is the concentration of the reference ligand (held constant in the assays where the test
ligand is treated as an antagonist). Finally, n is the transducer slope factor which was held to 1
for analysis. For the β-arrestin-2 and ERK1/2 assays, the U69,593 curve was first fit to the
reference ligand equation. These parameters were then used to fit the data from the test ligand
both using the agonist and antagonist equations. Initial parameters and constraints were held as
described in Stahl et al. 2015.71
Reference ligand:
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 +

𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚
1+(

1 + 10./01234567 8 ;
)
10./91234567 8

Test ligand as an agonist:
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 +

𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚
1 + 10(/01234<6=< )
1 + ( (/9123>9123>?) );
10

Test ligand as an antagonist:
𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚

𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 +
1+(

1 + 10.?01234567 8 + 10(/0 1234<6=< ) ;
)
10(?9123A ) + 10(/9123>9123>?)
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2.3 Biochemical studies and imaging
2.3.1 Stable-isotope labelling in cell culture (SILAC) and immunoprecipitation
HEK 293 cells expressing a KOR tagged with an N-terminal FLAG sequence (DYKDDDDK)
were grown to confluence in 10cm dishes, in DMEM media containing light or heavy amino acids
(15N Lysine and Arginine) (all media from SILAC Protein Quantitation Kit (Trypsin), DMEM,
ThermoFisher, Waltham, MA, USA). Cells were grown until cells in heavy media had at least 95%
heavy amino acid incorporation. For immunoprecipitations, cells were lysed in lysis buffer (10%
v/v glycerol, 75mM Tris pH 7.4, 2mM EDTA, 0.5% v/v digitonin) with PhosSTOP phosphotase
inhibitor and cOmplete mini EDTA-free protease inhibitor cocktails (Sigma Aldrich, St Louis,
MO, USA) and membranes lysed by passage through a 25 gauge needle and subsequent incubation
and centrifugation. For SILAC experiments, cell lysates were mixed together and incubated with
Anti-FLAG M2 agarose beads (Anti-FLAG M2 Affinity Gel, Sigma, St. Louis, MO, USA)
overnight. Beads were washed with ice-cold lysis buffer (0.1% v/v digitonin) and proteins were
eluted with 1X LDS sample buffer.
2.3.2 Mass spectrometry analysis
Samples were run on Bis-Tris protein gels and gel samples were subjected to in-gel tryptic
digestion.72 The resulting peptides were extracted and purified, analyzed by LCMS using a
Thermo Orbitrap Fusion Lumos mass spectrometer, with a Thermo Easy-nLC 1200 HPLC and a
Thermo Easy-Spray electrospray source (ThermoFisher, Waltham, MA, USA). Identification and
quantification of proteins was performed by searching against a human protein sequence
database with the MaxQuant software (version 1.2.2.5).73

19

2.3.3 Immunofluorescent sample preparation and imaging
Coverslips or plastic-bottomed 96-well plates were coated in poly-D-lysine, and HEK cells
expressing a N-terminal GFP-tagged KOR were plated and grown to 80% confluence. Cells were
then serum starved for 16-24 hours and cells were treated with the appropriate concentration of
drug in serum-free media for 1 hour. Cells were fixed and permeabilized with ice-cold methanol,
and blocked for at least 1 hour in Tris Licor Blocking Buffer (LiCor Biosceinces, Lincoln, NE,
USA). Cells were stained with pan-14-3-3 primary (14-3-3 (pan) Antibody 8312, 1:50, Cell
Signaling Technology, Danvers, MA) and Alexa-647 secondary (1:500, Thermo Fisher
Scientific, Waltham, MA, USA) and subsequently with DAPI (Sigma Aldrich, St Louis, MO) for
nuclear visualization. If coverslips were used, coverslips were mounted on slides using ProLong
Diamond Antifade Mountant (Invitrogen, Eugene, OR, USA). Coverslip images (Figure 4.12)
were taken using an Olymbus IX71 spinning disk microscope. 96-well plates were imaged using
LSM 780 laser scanning confocal microscopy. Z-stacks from confocal microscopy were
deconvoluted using Autoquant software (Media Cybernetics, Rockville, MD, USA) and nuclear
localization was quantified using Imaris (Oxford Instruments, Abingdon, UK).
2.4 Animal studies
2.4.1 Animals
Male C57BL6 mice (9-13 weeks, 20-30g, Charles River Laboratories, Wilmington, MA, USA)
were used in all studies. Mice were housed, four to a cage, in sound attenuated chambers with
individual light controls, in stress-minimized rooms, with a reverse 12 hour light/dark cycle, and
food and water were provided ad libitum. All animals were housed for at least one week, with
daily handling, prior to studies. Animals were housed and euthanized in a manner approved by
The Rockefeller University Institutional Animal Care and Use Committee.
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2.4.2 Prolactin release
Mice were injected intraperitoneally with KOR agonists in saline (U50,488 and nalfurafine) or a
vehicle of 10% v/v ethanol, 10% v/v Tween-80 and 80% distilled-deionized water (BPHA,
MCBPHA, MCPPHA) 30 minutes prior to sampling. LY2444296 or vehicle pretreatment, if
applicable, was given by intraperitoneal injection 60 minutes prior to sampling. Trunk blood was
collected by rapid decapitation, followed within 2 hours by preparation of serum. Serum
prolactin levels were determined using a commercially available enzyme-linked immunoassay
(AbCam, Cambridge, UK) following dilution of serum 5-fold in assay buffer.
2.4.3 Rotarod Assay
Rotarod experiments were conducted with mice using a dedicated rodent rotarod apparatus, with
up to five animals tested concurrently (IITC Life Science, Woodland Hills, CA, USA). Rotarod
rotation rate began at 3 rotations per minute, and ramped to 30 rotations per minute over the
course of 300 seconds, at which time the assay was terminated and animals returned to their
home cage. Animals were acclimated to the rotarod on at least two occasions prior to the day of
the test. On the day of the test, baseline times for each animal to fall off the rotarod were
recorded. Animals that failed to remain on the rotarod for at least 150 seconds during baseline
testing were removed from the analysis. Mice were then injected intraperitoneally with vehicle or
compound, and rotarod measurements conducted, beginning 0-2 minutes after injection, and then
subsequently at select time points thereafter. Rotarod performance was calculated as the percent
of baseline time spent on the rotarod, and Pearson r correlation between rotarod performance and
in vitro parameters was done using GraphPad Prism 7.0 (GraphPad Software, San Diego, CA,
USA).
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2.4.4 Conditioned-place preference and aversion assays
Mouse place preference chambers had three distinct compartments, separated by
removable doors (ENV-3013; Med Associates, St. Albens, VT, USA). The central chamber had a
solid grey floor and grey walls. The larger, black and white compartments had stainless steel rod
and mesh floors, respectively. Experiments were performed in dimly-lit, sound attenuated
chambers. All studies used a biased, counterbalanced design. During the pre-conditioning
session, each animal was placed in the center compartment with the doors between chambers
open. Time spent in each chamber was recorded for 30 minutes.

Conditioned-place aversion
For the conditioned-place aversion experiment with BPHA (Figure 5.7), animals were
assigned their preferred compartment (black or white) from the pre-test as the drug paired
chamber. Mice received 4 days of conditioning, with two conditioning sessions (AM and PM)
per day. Mice were counterbalanced for AM or PM drug-paired conditioning sessions, and
sessions were at least 3 hours apart. During each conditioning session, mice were pretreated with
an intraperitoneal injection with BPHA (30mg/kg) or vehicle (10% ethanol, 10% Tween-80, 80%
water). Then, mice were immediately placed in the appropriate chamber (with doors shut) for 30
minutes (Figure 2.1). After the four conditioning days, the post-test was performed in which
mice were allowed free access to all chambers and time spent in each chamber was recorded for
30 minutes.
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Figure 2.1. Conditioned place aversion assay set-up. Used for Figure 5.7, testing aversion with
diphenethylamine compound BPHA.

Conditioned-place preference
For conditioned-place preference experiments (Figures 5.8 and 5.9), as well as aversion
of nalfurafine and U50,488 (Figures 5.5 and 5.6), animals were assigned their non-preferred
compartment (black or white) from the pre-test as the drug paired chamber. Mice received two
days of conditioning, with two conditioning sessions (AM and PM) per day. Mice were
counterbalanced for AM or PM drug-paired conditioning sessions, and sessions were at least 3
hours apart. During each conditioning session, mice were pretreated with an intraperitoneal
injection with KOR agonist (U50,488, nalfurafine or saline) for 15 minutes, before saline or
cocaine injection. Then, mice were immediately placed in the appropriate chamber (with doors
shut) for 30 minutes (Figure 2.2). After the two conditioning days, the post-test was performed in
which mice were allowed free access to all chambers and time spent in each chamber was
recorded for 30 minutes.
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Figure 2.2. Conditioned-place preference assay set-up. Used to test the blockade of cocaine
reward by KOR agonists U50,488 (Figure 5.8) and nalfurafine (Figure 5.9). Also used to test
aversion caused by KOR agonists U50,488 (Figure 5.5) and nalfurafine (Figure 5.6).

2.4.5 Intravenous cocaine self-administration
Adult mice (8-10 weeks) were anesthetized with 5% vaporized isoflurane, and maintained on 23% isoflurane for the duration of the surgery. A catheter approximately 6 cm in length was
inserted into the right jugular vein, up to a silicon ball placed 1.2-1.3 cm from the end of the
catheter. Starting 48 hours after surgery, catheters were flushed with physiological saline
containing heparin and the antibiotic gentamicin every other day to maintain catheter patency.
For the IVSA experiments, mouse self-administration chambers were used inside sound
attenuating boxes (ENV-307W; Med Associates, St. Albens, VT, USA). Each self-administration
chamber contained a wall with two small holes, one defined as active and one defined as
inactive. Mice were tested for 2 hours daily, with infusions of 0.5 mg/kg/infusion cocaine on an
FR1 schedule following each active nose poke. During infusion, a cue light above the active hole
was illuminated and then followed by a 20-second “time-out” period during which no infusions
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could occur. Pretreatment experiments began when mice reached acquisition criteria, between 610 days after IVSA sessions began, depending on the animal. Acquisition criteria were: >70% of
nose pokes in the active hole and <20% variation across two consecutive days. On each
pretreatment day, mice were given IP injections of a KOR agonist (U50,488 or nalfurafine) or
saline immediately before being placed in self-administration chambers. For the antagonist
blockade experiment (Figure 5.11), mice were pretreated with 3mg/kg LY2444296 or vehicle by
IP injection, and then given the KOR agonist or saline injections before being immediately
placed in self-administration chambers (Figure 2.3). Catheter patency was checked weekly by
infusion of ~30µL ketamine (5mg/mL), and only data from mice that passed this catheter
patency test (defined as loss of muscle tone within a few seconds after ketamine infusion) were
included in data analysis.

Figure 2.3. KOR agonist pretreatment set-up for cocaine IVSA

2.4.6 In vivo data analysis
Analysis of variance (ANOVA) tests were used to assess the effects of drug treatments on in
vivo endpoints. Post-hoc multiple comparison tests were chosen based on relevant comparisons.
Dunnett’s post-hoc test was used to compare treatment groups to vehicle or saline control
groups. Newman-Keuls post-hoc test was used to compare all treatment groups to each other, as
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was often the case for antagonist pretreatment experiments for KOR specificity. Finally, Sidak’s
multiple comparison post-hoc test was used in the case of the intravenous self-administration
experiments, in which there were repeated measures on time.
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CHAPTER 3. G-PROTEIN VS ARRESTIN BIAS OF KOR LIGANDS

3.1 b-Arrestin-2 and G-protein signaling pathway activation by KOR ligands
While ligand bias can be measured between any signaling events or effectors downstream
of an activated GPCR, “bias” most commonly refers to the difference between the receptorproximal G-protein and b-arrestin signaling pathways.74 Several studies have examined the
ability of different KOR agonists to activate both of these signaling pathways, using a variety of
different cell lines and endpoints. To measure G-protein recruitment to the receptor directly,
bioluminescence resonance energy transfer (BRET) and radioligand binding assays ([35S]GTPgS)
are frequently used.66 Importantly, the [35S]GTPgS assay can be carried out in native tissue
without genetic manipulations – this method has been optimized by the Bohn group to measure
endogenous G-protein coupling in rodent striatum.66 Second messengers downstream of Gprotein activation, such as the inhibition of cAMP release and increased calcium release, are also
used to measure G-protein activity downstream of the KOR. Finally, downstream signaling
pathways such as ERK1/2 have also been used occasionally as proxies for G-protein activation.
In contrast to G-protein recruitment, heterologous cell lines must be used in BRET or
enzyme fragment complementation assays to measure b-arrestin recruitment directly, with
genetically modified versions of one of the isoforms of b-arrestin. Downstream responses such
as internalization or p38 phosphorylation have also been used to measure arrestin recruitment
indirectly.
In addition to the wide array of endpoints that have been used to measure these signaling
pathways in the literature, it has also been shown that ligand bias is context-dependent, meaning
the same ligand can differentially activate signaling pathways depending on the cell line or tissue
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tested, for many GPCRs including the KOR.75 These factors make it very difficult to compare
across studies, and to draw any generalizations about the actions of biased ligands at the KOR.
The goal of this work, the majority of which was published in ACS Chemical
Neuroscience in 2019,34 was to compare the G-protein and b-arrestin-2 recruitment of 21,
structurally diverse KOR ligands (Figure 3.1) in one cellular context. Here, we used the
PathHunter U2OS hOPRK1 cell line, measuring G-protein signaling using the [35S]GTPgS assay
and b-arrestin-2 recruitment using the PathHunter DiscoverX enzyme fragment complementation
assay. By using a single context, we could compare the activity of these ligands within their
structural classes, and between structural classes.

3.1.1 Diverse KOR agonists tested for signaling properties
Most studies of the signaling properties of KOR agonists examine individual structural
classes of ligands, with a few studies investigating larger sets of KOR ligands for specific
signaling properties.55 In this study, we aimed to examine a wide range of structurally diverse
ligands for their early, receptor-proximal signaling properties at the KOR in a single cellular
context. By using such a structurally diverse group of ligands, including the endogenous opioid
neuropeptide dynorphin A (1-17), we could potentially draw more generalizable conclusions
about the relationships between in vitro signaling properties and in vivo effects of KOR agonists.
First, the endogenous peptide ligand dynorphin A (1-17) was tested (Figure 3.1 A).
Dynorphin peptides are cleaved from a precursor protein into several different lengths, with
varying specificity for the opioid receptors. The form tested here, dynorphin A (1-17), is the
most KOR-specific of the Dynorphin peptides and responsible for the majority of endogenous
KOR activation.76,77 In addition to dynorphin A (1-17), the other naturally-occurring compound
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tested here was the natural product salvinorin A (Figure 3.1 A). Salvinorin A is a nonnitrogenous diterpene that is structurally unrelated to all other opioid ligands, and was recently
characterized as a potent, selective KOR agonist.30 Like many other KOR agonists, salvinorin A
has considerable aversive, psychotomimetic and dysphoric properties in clinical and preclinical
studies.31,78 This discovery led to the development of salvinorin-based derivatives for KORtargeted drug discovery. For example, the semi-synthetic analog mesyl salvinorin B, tested here
as well, was previously characterized in vivo for its improved side-effect profile compared with
the parent natural product salvinorin A (Figure 3.1 A).79
The most extensively-studied group of synthetic, selective KOR agonists are the
arylacetamide compounds (Figure 3.1 C), based on the structure U50,488.80 There has been
extensive preclinical and in vitro pharmacology characterizing these compounds, however very
few additional human studies have been conducted because of the negative side effects identified
in early studies of arylacetamide agonists in humans, including spiradoline (U62,066E).26–28
While the naturally-occurring and arylacetamide groups of compounds are all relatively
KOR-selective, we also tested several morphinan compounds that are better known for their
activity at other opioid receptors (Figure 3.1 B). Nalmefene, naltrexone, buprenorphine and
nalbuphine are all clinically-utilized compounds that are primarily recognized for their MOR
activity. Nalmefene and naltrexone are MOR antagonists that have been previously studied for
KOR partial agonism or antagonism.32 Nalmefene is currently approved to treat alcoholism in
Europe. Naltrexone is approved to treat opioid addiction and alcoholism in the US under the
brand name Vivitrol, among others. Buprenorphine is also approved to treat opioid addiction,
however it is a partial agonist at the MOR. Buprenorphine has also been reported to bind to the
KOR, with reports of both partial agonism and antagonism.81,82 Nalbuphine is also a MOR partial
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agonist used to treat pain clinically, and has been shown to have partial KOR activity in certain
signaling pathways.83 All four of these morphinans have shown varying levels of KOR agonism
for G-protein signaling, but very little activity in b-arrestin-2 recruitment or internalization
assays previously.
The final morphinan compound studied was nalfurafine, which is clinically approved to
treat pruritus in Japan under the name Remitch. Nalfurafine is a KOR agonist with some MOR
activity, with ~2-10 fold binding selectivity for KOR over MOR.35 Nalfurafine is notable for its
very high potency at the KOR – the daily oral dose of Remitch for humans is 2.5µg. There have
been reports of signaling at both the G-protein and b-arrestin-2 pathways, however
measurements of ligand bias between the two pathways vary between studies.35,36 One study, for
example, used downstream signaling kinases ERK1/2 and p38 as readouts for G-protein and barrestin-2 signaling, respectively, to suggest that nalfurafine was biased for G-protein signaling
over b-arrestin-2 signaling. Other groups have suggested that nalfurafine is unbiased because it
shows full efficacy in assays for both signaling pathways.
In addition to these groups of well-characterized KOR ligands, we also tested two
recently-described structural classes (Figure 3.1 D and E). The quinoxaline compounds WMS
0611 (which was first described as a peripherally-restricted KOR agonist) and 0610 by
Bourgeois, et. al. 2014 and the diphenethylamine family of compounds first described by Spetea,
et. al. 2012 were also tested. 64,84 BPHA (Compound 5 of Spetea et. al., 2012), MCBPHA
(HS665 of Spetea et. al., 2012), MCPPHA (Compound 3 of Erli et. al., 2017) and HS666 (Spetea
et. al., 2017) were further characterized in later studies for G-protein vs arrestin bias, as well as
other KOR-mediated in vivo endpoints in mice.85–87 Compounds 3G1 and 3G2, which were
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novel to our 2019 ACSCN study, are structurally related to the diphenethylamines, and included
in this class as well.34
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Figure 3.1. Structures of KOR agonists tested
Structures are arranged according to compound classes: A. the endogenous ligand dynorphin
A(1-17), the natural product salvinorin A and the derivative mesyl salvinorin B; B. morphinan
compounds; C. arylacetamide compounds; D. quinoxaline compounds; E. diphenethylamine
compounds.
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3.1.2 b-Arrestin-2 enzyme fragment complementation by KOR ligands in DiscoverX U2OS
Cells
We tested each compound for b-arrestin-2 recruitment using the DiscoverX PathHunter
enzyme fragment complementation (ECF) assay system. The DiscoverX PathHunter U2OS cell
line used expressed an enzyme-fragment-linked human KOR, as well as an enzyme-fragmentlinked b-arrestin-2, used for signal detection. All responses were blocked with KOR-selective
antagonist nor-Binaltorphimine (norBNI) to determine KOR-selectivity. In Figure 3.2, potency
(EC50) and maximal efficacy (Emax) values are given as averages of 3 separate experiments, with
4 technical replicates per experiment alongside representative dose-response curves. The
maximal efficacy of all other compounds was compared to the maximal efficacy of a
concurrently run U69,593 dose-response curve, as U69,593 was used as the reference agonist in
these experiments. The tables also include a LogRAiArr value, described in further detail in
Subsection 3.2.1, that compares activity of each ligand to the reference agonist U69,593.
In this assay, the reference agonist U69,593 robustly recruited b-arrestin-2, with a mean
EC50 of 683nM (Figure 3.2). The endogenous ligand dynorphin A (1-17) was more potent than
the reference agonist, as was the natural product salvinorin A. Mesyl salvinorin B, a derivate of
salvinorin A, had similar activity to that of the reference agonist (Figure 3.2 A).
The other arylacetamide compounds, which are structurally related to the reference
agonist U69,593 (Figure 3.1 C), all showed robust b-arrestin-2 recruitment with higher potencies
and similar maximal efficacies compared with U69,593 (Figure 3.2). The compound GR89,696
was the most potent compound tested in this assay, with an average EC50 of 13.7nM.
The morphinan compounds, by contrast, overall showed very little b-arrestin-2
recruitment (Figure 3.2 B). Nalbuphine showed very modest b-arrestin-2 recruitment, with an
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EC50 of over 4000nM and only 26% maximal efficacy. Nalmefene, naltrexone and
buprenorphine did not demonstrate any measurable b-arrestin-2 recruitment in this assay (Figure
3.2 B). Dose-response curves of these compounds were tested against a steady concentration of
300nM U69,593 in this assay, in order to determine their ability to antagonize b-arrestin-2
recruitment by the reference agonist. In this paradigm, nalmefene, naltrexone and buprenorphine
were potent antagonists of this signaling pathway (Figure 3.3). The exception in the morphinan
class of compounds was nalfurafine, which had very robust b-arrestin-2 recruitment. Nalfurafine
had a similar maximal efficacy to the reference agonist U69,593 and greater potency with a mean
EC50 of 38.3nM (Figure 3.2 B).
Overall, the more recently described quinoxaline and diphenethylamine compounds did
not show much b-arrestin-2 recruitment (Figure 3.2 D, E). WMS 0611 had more activity in this
assay than the closely-related WMS 0610, with average EC50 values of 28µM and 4.3µM,
respectively. The diphenethylamines HS666 and BPHA were antagonists in this assay (Figure
3.2 E), with full blockade but relatively large IC50 values (Figure 3.3). The remaining
diphenethylamines (MCBPHA, MCPPHA, 3G1 and 3G2) were partial agonists for b-arrestin-2
recruitment (Figure 3.2 E).
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Figure 3.2. b-Arrestin-2 EFC by KOR ligands and representative dose-response curves
Figures are arranged by structural class: (A) the endogenous ligand dynorphin A (1-17), the
natural product salvinorin A and its derivative mesyl salvinorin B, (B) morphinan compounds,
(C) arylacetamide compounds, (D) quinoxaline compounds and (E) diphenethylamine
compounds. Emax values were calculated as the percentage of maximum U69,593 response from a
concurrent U69,593 dose-response curve. Average EC50 and Emax values are represented as
averages of 3 separate experiments with 4 replicates per experiment (±SEM). For compounds
with low Emax values, data from the antagonist curves were fit to the operational model of partial
agonism to calculate LogRAi values (*). Representative dose-response curves are shown
alongside a representative U69,593 dose-response curve, in black in each graph. U69,593
stimulation was between 160 and 250% above baseline (800-2000 CUs).
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Figure 3.3. Blockade of U69,593-induced b-Arrestin-2 EFC by KOR ligands and
representative dose-response curves. Compounds from (A) morphinan and (B)
diphenethylamine classes of compounds with low Emax values were tested as antagonists to block
arrestin enzyme fragment complementation by 300nM U69,593. Maximum inhibition values
were calculated as the percentage of 300nM U60,593 response. Average IC50 and Max Inhibition
values are represented as averages of 3 separate experiments with 4 replicates per experiment
(±SEM).
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3.1.3 [35S]GTPgS binding by KOR ligands in DiscoverX U2OS cells
Each compound was tested for G-protein activation using the [35S]GTPgS radioligand
binding assay. This assay was done using membranes prepared from the same DiscoverX
PathHunter U2OS cell line used for the b-arrestin-2 recruitment assay, in order to determine
differential signaling mechanisms in the same context. All responses were antagonized with
norBNI to determine KOR-selectivity, as this assay will measure any G-protein activity in the
cell line. In Figure 3.4, potency (EC50) and maximal efficacy (Emax) values are given as averages
of 3 separate experiments, with 4 technical replicates per experiment alongside representative
dose-response curves. The tables also include a LogRAiG value, described in further detail in
Subsection 3.2.1, that compares activity of each ligand to the reference agonist U69,593.
The reference agonist U69,593 caused robust G-protein activation in this assay, with an
average EC50 value of 3.3nM (Figure 3.4). Many compounds were more potent than U69,593 in
this assay, however. Dynorphin A (1-17) was very potent for G-protein activation, with an
average EC50 of 0.04nM (Figure 3.4 A). Both salvinorin A and mesyl salvinorin B were more
potent than the reference agonist as well, however all of these compounds had maximal
efficacies below 100%.
The arylacetamide compounds showed robust G-protein activation as well, with EC50
values ranging from 0.03nM to 0.6nM (Figure 3.4 C). The arylacetamide compound GR89,696
was the most potent compound tested in this assay, as it was in the b-arrestin-2 recruitment
assay. The morphinan compounds also exhibited potent activity in this assay, and had maximal
efficacy values ranging from 44.5% (nalbuphine) to 84.3% (nalfurafine) (Figure 3.4 B).
The quinoxaline and diphenethylamine compounds had variable G-protein activity
downstream of the KOR, despite the structural similarity within groups (Figures 3.1 D, E). WMS
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0611 was ~4-fold more potent than WMS 0610 for G-protein activation. EC50 values for the
diphenethylamine series of compounds ranged from 0.5nM for MCPPHA to 22.7nM for HS666,
with all compounds having similar maximal efficacies (75-87%) (Figure 3.4 E).
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Figure 3.4. [35S]GTPgS binding by KOR ligands and representative dose-response curves
Figures are arranged by structural class: (A) the endogenous ligand dynorphin A (1-17), the
natural product salvinorin A and derivative mesyl salvinorin B, (B) morphinan compounds, (C)
arylacetamide compounds, (D) quinoxaline compounds and (E) diphenethylamine compounds.
Average EC50 and Emax values are presented in tables as averages of 3 separate experiments with
4 replicates per experiment (±SEM). Emax values were calculated as the percentage of maximum
U69,593 response from a concurrent U69,593 dose-response curve. LogRAi values were
estimated from these average EC50 and Emax values. Representative dose-response curves are
shown alongside a representative U69,593 dose-response curve, in black in each graph. U69,593
stimulation was between 35 and 70% above baseline (2000-8000 DPM).
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3.1.4 GTPg35S binding by KOR ligands in mouse striatum tissue
While measuring arrestin recruitment directly requires heterologous cell lines, G-protein
binding can be measured directly in native tissue. In order to examine G-protein signaling in a
more physiologically-relevant context, we also investigated G-protein signaling in mouse striatal
tissue, where there is dense KOR expression.88 Mouse caudate putamen and nucleus accumbens
were dissected and homogenized, and membranes were prepared for radioligand binding assays
as described in Zhou, et. al. 2015.66
First, we optimized the preparation of the striatal membranes for KOR binding, and
measured G-protein binding in the mouse striatum using the [35S]GTPgS assay. The full
reference agonist U69,593 robustly stimulated G-protein binding in the mouse striatum samples
(Figure 3.5 A), and this effect was fully blocked by the KOR-selective antagonist norBNI
(Figure 3.5 B). Nalmefene, which has been previously shown to be a partial agonist at the KOR,
showed less than 50% G-protein binding compared to U69,593 in the mouse striatum (Figure 3.5
B). EC50 values for both compounds were higher than in U2OS cells, but consistent in their rank
order (Figure 3.4 B, 3.6 A).
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Figure 3.5. [35S]GTPgS binding in mouse striatum tissue
Mouse striatum tissue was homogenized and incubated with 10nM [35S]GTPgS and increasing
concentrations of test compounds. Emax values are shown here as a percentage of max U69,593
response (2000-8000 DPM). (A) Dose-response curve for U6,593 had an EC50 of 34.7nM and
nalmefene had an EC50 of 3.1nM. (B) Emax values alone are shown for co-treatment of tissue with
10µM U69,593 and 10µM antagonist norBNI and treatment of tissue with 20µM nalmefene.
3.1.5 Discussion
Many studies have pointed out the caveats of studying GPCR signaling pathways using
heterologous cell systems. Unfortunately, it is currently necessary to use modified receptor and
arrestin proteins in order to directly measure arrestin recruitment. In addition to the enzyme
complementation assay used here, other methods of measuring arrestin recruitment also utilize
fusion proteins, such as FRET and BRET. The less direct methods of measuring arrestin activity,
such as internalization or p38 phosphorylation, do not require modified proteins, however, they
do not account for the potential contributions of other signaling pathways.
In addition to the issue of modified protein structure and function, there is also recent
evidence that GRK2 expression levels affect measurements of arrestin signaling at the mu opioid
receptor,89 including in the DiscoverX PathHunter assay.45 Specifically lower levels of GRK2
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expression were shown to mask partial agonism by decreasing overall signal. It is possible that
the lack of GRK2 expression in the U2OS cells used here is leading us to underestimate the
amount of arrestin recruitment caused by some agonists, such as the morphinan compounds that
showed almost no measurable arrestin recruitment (Figure 3.2 B). However, our results are
consistent with previous studies of morphinan compounds using other methods to assess arrestin
activation. For example, nalbuphine was shown to cause minimal internalization,54 and
buprenorphine also demonstrated minimal arrestin recruitment in a BRET assay that included
GRK2 co-expression.81
Using the U2OS DiscoverX PathHunter cell line for the [35S]GTPγS assay, we found an
unusually high level of G-protein coupling compared to previous studies. In particular, the
morphinan series of compounds was found to have higher Emax values in the [35S]GTPgS assay
than expected – most published reports give maximal efficacy of less than 50% (compared to
reference agonists) for compounds nalmefene, naltrexone and nalbuphine, where we
demonstrated maximal efficacy between 70-80% compared to the full agonist U69,593 (Figure
3.4 B). This assay has been reported to be particularly susceptible to cellular context, because of
different coupling levels for different G-proteins,81 as well as a saturation effect if levels of
receptor expression are too high. While the goal of this study was to investigate both signaling
pathways within the same cell line, in future studies it would be beneficial to measure G-protein
signaling directly in disease-relevant tissue.
To investigate G-protein activation in a more physiologically-relevant context, we tested
several compounds for [35S]GTPγS binding in mouse striatal tissue. This assay showed similar
levels of [35S]GTPγS binding for the reference agonist U69,593, and demonstrated lower
efficacy agonism for the morphinan compound nalmefene that is more consistent with both
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previous literature and known effects in humans (Figure 3.6 B). Previous studies have shown that
nalmefene is a partial KOR agonist in humans, using the serum prolactin as a biomarker for
KOR activation.32 Additionally, data from humans in clinical trials and post-marketing data from
the use of nalmefene to treat alcohol addiction indicates that nalmefene does not cause side
effects like hallucinations or psychotomimesis,90 while full KOR agonists tested in humans, such
as spiradoline (U62,066E) and salvinorin A do.28,31 Together with in vitro G-protein activation
data from other cell lines and studies, these data indicate that nalmefene is likely acting as a
partial KOR agonist in the therapeutically-relevant setting, and the data from the striatal tissue
[35S]GTPγS experiment more accurately models that setting than the [35S]GTPγS data from the
U2OS cells (Figures 3.4 B, 3.6 B). While this system is promising for measuring G-protein
binding, it is still relatively inconsistent. Additional troubleshooting and optimization are
required, and then additional compounds can be examined in the future.
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3.2 KOR ligand bias and relationships between in vitro metrics and in vivo activity
In order to quantify ligand bias for these compounds in our U2OS cell system, we first
needed to control for systemic factors. For example, directly comparing the EC50 of a compound
in the [35S]GTPgS assay and the b-arrestin-2 assay will not give a good measurement of bias
because of differences in assay kinetics. To control for this kind of “system bias”, we chose to
use U69,593 as our reference ligand to run alongside all the other KOR agonists tested here.
Each ligand could then be compared against the reference ligand, to control for assay-specific
factors. All measurements of ligand bias are dependent on the reference agonist chosen, and this
is another part of the “context” that is important to describe when describing a biased agonist.
For studies of the KOR, several different ligands have been used as the reference. Several
groups have used dynorphin A (1-17), because it is the major endogenous neuropeptide.54 We
chose U69,593 as the reference agonist because it has been widely-characterized in many
different labs as a full, unbiased agonist at the KOR with full activation of both the G-protein and
b-arrestin-2 signaling pathways using several different assays.
To compare the activity of a test ligand to the reference ligand, we used a method based
on the operational model of partial agonism. First described by Black and Leff in the 1980’s, this
model uses dose response data from both the test agonist and the reference agonist to calculate a
measurement of intrinsic relative activity (RAi).69 This metric takes into account both the
potency and maximal efficacy of the test agonist, and is presented here as the LogRAi. While
this metric can be calculated from fitting dose-response data directly to the operational model,
when the Hill slope is equal to 1 it can be estimated using the Emax and EC50 values of the doseresponse curve. For compounds that had very low intrinsic activity in a given assay, and
therefore could not be fit to a traditional sigmoidal dose-response curve, we used a modified

48

version of the operational model (described by Stahl at al. 2015)71 to directly calculate the
LogRAi value from dose-response data. LogRAi values were calculated for each compound for
both G-protein and arrestin assays, and compared to quantify ligand bias between the two
signaling pathways (DLogRAi).
We could then use this composite DLogRAi metric, as well as metrics from both the in
vitro assays alone, to investigate relationships between agonist activity in vitro and in vivo.
Because of the use of heterologous cell lines and the context-dependent nature of many of these
signaling pathways, it is difficult to use in vitro activity to predict in vivo behaviors. This is
critical, however, for drug discovery efforts. The Bohn lab recently demonstrated that a
calculated composite “bias factor” for MOR agonists tested in vitro correlated with the
therapeutic window between antinociceptive effects and respiratory depression in mice.46
Similarly, the Van Rijn lab demonstrated that efficacy measured in an arrestin assay correlated
with increased alcohol intake caused by DOR activation in mice.91 Both of these studies
demonstrate how these in vitro-in vivo relationships could help to improve drug discovery efforts
for safer and more effective opioid receptor agonists. In these studies, we looked at the
relationship between KOR agonist activity in vitro and sedation in mice, measured by the rotarod
assay.

3.2.1 Quantifying ligand activity bias with intrinsic relative activity metric
To compare each compound to U69,593, we calculated the LogRAiG and LogRAiArr,
which give a quantitative comparison of the activity of each compound to the reference agonist
U69,593 in the given assay (Figures 3.2 and 3.3). By definition the reference agonist U69,593
has a LogRAi of 0. A value larger than 0 indicates a compound that has higher relative intrinsic
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activity in that assay, and any value below 0 indicates a compound that has less activity relative
compared to the reference agonist in that assay, as seen in Figures 3.2 and 3.3. In certain cases
where the maximal efficacy was very low in the b-arrestin-2 recruitment assay, a dose-response
curve could not be fit to the data and no Emax and EC50 value was available for LogRAi
estimation. This was the case for several morphinan compounds, as well as the
diphenethylamines HS666 and BPHA (Figure 3.3). In these cases, additional dose-response
curves of the compounds were tested in the presence of a steady concentration of U69,593 to
determine the antagonist properties of the compounds. These antagonist curves were then fit to a
modified version of the operational model of partial agonism and the LogRAi values were
calculated from these parameters.71
In order to compare the bias of a compound between the two signaling pathway assays,
the DLogRAiG-Arr was calculated as (DLogRAiG-Arr = LogRAiG - LogRAiArr) (Figure 3.6).
Almost all the compounds tested were G-protein biased in this system compared to the reference
agonist U69,593. Salvinorin A and its derivative mesyl salvinorin B were the most “balanced”
compounds tested, and most of the other arylacetamide compounds were also relatively unbiased
(Figure 3.6). The majority of the morphinan compounds, on the other hand, exhibited very robust
G-protein bias. The exception in this structural class was nalfurafine, which was the only
compound we tested that was biased for b-arrestin-2 recruitment over G-protein signaling (with a
negative (DLogRAiG-Arr value) (Figure 3.6). Both groups of recently-described KOR agonists, the
quinoxalines and the diphenethylamines, were G-protein biased with varying degrees of bias.
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Figure 3.6. DLogRAi measurements of bias for KOR ligands
The DLogRAiG-Arr values were calculated (LogRAiG - LogRAiArr) to quantify ligand bias for each
compound compared to the reference agonist U69,593. Positive DLogRAiG-Arr values indicate
bias for G-protein signaling over b-arrestin-2 signaling, while negative DLogRAiG-Arr values
indicate bias for b-arrestin-2 signaling over G-protein signaling, relative to the reference agonist
U69,593. DLogRAiG-Arr values were calculated using the average EC50 and Emax as described in
the methods from three separate experiments, and are shown here plus/minus combined standard
deviations.
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3.2.2 Correlation between ligand activity in vitro and in vivo sedation behavior
The goal of quantifying ligand activity in vitro was to develop a method to determine
which compounds have the desired therapeutic properties. In order to better understand which in
vitro measurements of ligand activity best modeled in vivo responses, we compared different in
vitro metrics for both the G-protein and b-arrestin-2 signaling assays to an in vivo measurement
of sedation / motor incoordination.
To assess the undesirable effects of sedation / motor incoordination, we used the rotarod
assay. In this assay, C57BLJ6 mice were trained to run on an accelerating rod and their baseline
ability to stay on the rod as it accelerates was recorded. Mice were then injected intraperitoneally
with drug and tested for rotarod performance. Ligands that caused sedation or motor
incoordination led to decreased rotarod performance compared to baseline (mice fell off of the
rod earlier than they had in their baseline run). We tested high doses of these compounds in this
assay, both to assess the maximum possible rotarod effect and to minimize the effect of differing
pharmacokinetic properties between compounds.
The maximum effect of most compounds tested occurred at 30 minutes post-injection.
Results are presented as the percentage of baseline rotarod performance (e.g. 100% of baseline
performance is no impairment) at this 30 minute timepoint. Consistent with previous studies, we
found that the arylacetamide compound U50,488 was very sedative at the high dose of 30mg/kg
(Figure 3.7). The morphinan compound nalfurafine was also very sedative, and more potent than
U50,488, with a similar effect at only 3mg/kg. Most of the diphenethylamine compounds tested
(MCBPHA, MCPPHA, 3G1 and 3G2) had a partial effect in this assay, with rotarod performance
between 54% and 70% of baseline performance (Figure 3.7). The diphenethylamine BPHA, on
the other hand, did not cause any measurable rotorod impairment (Figure 3.7). The morphinan
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compounds nalmefene and nalbuphine similarly did not cause any measurable rotarod
impairment, with rotarod performance close to 100% that of baseline testing (Figure 3.7).
This maximum effect on the rotarod test was then compared to several different in vitro
measurements of ligand activity using Pearson r correlation (Figure 3.8). There was a significant
correlation (r = -0.97, p<0.001) between the Emax measured in the b-arrestin-2 recruitment assay
and the maximum effect on the rotarod test (Figure 3.8 A). However, there was no significant
correlation between the Emax measured in the [35S]GTPgS assay and the rotarod performance
(Figure 3.8 C). Likewise, there was no correlation between the EC50 in the [35S]GTPgS assay or
the LogRAiG measurement of relative activity (Figure 3.8 D). Because so many of the
compounds tested in the b-arrestin-2 recruitment assay had very little intrinsic activity, the
correlation for the arrestin EC50 data is not shown. From the limited data available, there was no
significant correlation between arrestin EC50 and rotarod sedation. However, there was a
significant correlation (r = -0.96, p < 0.0001) between the LogRAiArr and rotarod performance
(Figure 3.8 B). Finally, there was a weaker, but significant, correlation (r = -0.76, p<0.05)
between the DLogRAiG-Arr measurement of ligand bias and rotarod performance (Figure 3.8 F).
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Figure 3.7. Rotarod sedation by select KOR ligands
Rotarod performance is reported here as the percentage of baseline performance 30 minutes after
intraperitoneal injection of 30mg/kg compound (except nalfurafine, at 3mg/kg). N = 7-8 animals
per group.
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Figure 3.8. Correlation of in vitro metrics with rotarod sedation
Pearson r correlations comparing in vitro measurements (X axis) with rotarod performance were
calculated for (A) b-arrestin-2 Emax, (B) b-arrestin-2 LogRAi, (C) G-protein Emax, (C) G-protein
EC50, (E) G-protein Emax, and (F) the DLogRAiG-Arr measurement of ligand bias. Both
measurements of b-arrestin-2 activity (A and B) as well as the measurement of ligand bias (F)
correlated significantly with rotarod activity.

3.2.3 Discussion
Using the U2OS DiscoverX PathHunter cell line for both the [35S]GTPgS and b-arrestin
signaling pathway assays and U69,593 as the reference agonist, we found the vast majority of the
compounds we tested to be G-protein biased agonists (Figure 3.6). Even compounds that had
previously been reported to be relatively unbiased compared to U69,593, such as salvinorin A,
were slightly G-protein biased in this system, as well as the other arylacetamide compounds that
are structurally very similar to U69,593. This indicates that U69,593 was uniquely effective at
recruiting b-arrestin in this system compared to the other agonists, however it also suggests that
our system was particularly sensitive to G-protein coupling over arrestin recruitment.
We found the majority of the morphinan compounds, namely nalbuphine, nalmefene,
naltrexone and buprenorphine, to be very G-protein biased (Figure 3.6). This is consistent with
previous reports of their ligand bias in these signaling pathways, even using other cell lines and
other endpoints.32,81 A study of ligand bias for MOR agonists demonstrated that measurements of
ligand bias are most resilient to differing context in the cases of “extreme” bias, when there is
little measurable activity at one of the signaling pathways.46 Nalfurafine, on the other hand, was
found to be arrestin-biased by our calculations (Figure 3.6), while it has been described as both
unbiased and G-protein biased using other cell lines and other end-points for G-protein and
arrestin signaling. In our hands nalfurafine had similar potency for G-protein signaling to the
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reference agonist U69,593. In the b-arrestin-2 recruitment assay, however, nalfurafine was ~20fold more potent than the reference agonist. This high potency in the b-arrestin-2 recruitment
assay then translated to a negative DLogRAiG-Arr value, which indicated arrestin-bias in our
system. Further investigation into the signaling properties of nalfurafine could help to explain its
unique behavioral profile compared to other KOR agonists.
The diphenethylamine series of compounds had varied bias profiles, with the compound
BPHA having a larger DLogRAiG-Arr value (indicating G-protein bias) while the remaining
compounds had DLogRAiG-Arr values closer to zero (Figure 3.6). Interestingly, BPHA was the
only diphenethylamine compound tested that had a non-cyclic side chain off of the central
amine, suggesting an important role for this part of the molecule in determining arrestin
recruitment (Figure 3.1 E). WMS 0610 and WMS 0611 differ only in one phenyl ring (Figure 3.1
D), however WMS 0610 was significantly more G-protein biased than WMS 0611 (Figure 3.6).
Data like these can be used in the future to help drive structure-activity relationship studies of
KOR ligands, to improve drug discovery efforts.
Finally, we investigated the relationships between the in vitro measurements and
quantifications of the activity of these ligands and their actual effect in an in vivo assay of
sedation / motor incoordination in mice. We found that measurements of arrestin recruitment
activity, including the maximum efficacy (Emax) and the LogRAi (which takes into account both
Emax and EC50) were significantly correlated with the maximum effect in the rotarod assay
(Figure 3.8 A, B). None of the measurements of G-protein activity, on the other hand, correlated
with this rotarod effect (Figure 3.8 C, D, E). This supports the hypothesis generated by previous
studies of single structural classes of biased KOR ligands that b-arrestin-2 recruitment is
involved in KOR-mediated sedation as measured by the rotarod assay.51,52,86 While the
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quantification of overall G-protein vs arrestin bias (DLogRAiG-Arr) did have a significant
correlation (Figure 3.8 F), it was weaker than the arrestin correlations alone. Together, these data
suggest that a G-protein biased agonist at the KOR could be more likely to have an acceptable
therapeutic “window”, due to a lack of sedative side effects even at high doses.
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CHAPTER 4. OTHER SIGNALING PATHWAYS DOWNSTREAM OF THE KOR

4.1 ERK1/2 and mTOR signaling pathway activation by KOR ligands
In addition to profiling the G-protein and b-arrestin-2 recruitment of the ligands that target
the KOR, there are several other signaling pathways that have been shown to be important for
KOR activity and specifically addiction-related behaviors. Various mitogen-activated-protein
kinases (MAPK), for example, have been shown to be phosphorylated by KOR agonist activity,
including extracellular-related kinases 1 and 2 (ERK1/2).92 ERK1/2 has also been shown to be
important for the incubation of cocaine craving, and other drug-related behaviors.93 There have
been varying results in the literature linking ERK1/2 phosphorylation at different time points to
either G-protein or arrestin signaling, however it is difficult to draw larger generalizations across
these studies because of the diverse array of cell lines, time points and KOR agonists used.
Importantly, a study of a series of novel triazole KOR agonists demonstrated that ERK1/2
phosphorylation can be modulated independently of G-protein vs arrestin bias.62 This was one of
the first studies to suggest that downstream signaling pathways like ERK1/2 should be tested
independently of G-protein and arrestin pathways, and that the pharmacological profile of KOR
agonists had the potential for much more diversity than was previously believed.
The mTOR signaling pathway is now known to be important for integrating cellular
signaling in the central nervous system.94 More recently, the mTOR pathway has been shown to
be important for KOR-mediated behavior, specifically aversion.36,39 It is unclear, however, if and
how mTOR activation is related to G-protein or arrestin signaling pathways. In this study we
tested the same set of diverse KOR agonists (Figure 3.1) for ERK1/2 phosphorylation and
mTOR pathway activation and compared their activity in these pathways to their activity in the
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early signaling pathways (G-protein and arrestin) tested in Chapter 1. This ERK1/2 and mTOR
signaling pathway data was also included in the 2019 publication with G-protein and arrestin
signaling data for these compounds.34

4.1.1 ERK1/2 phosphorylation by KOR ligands in HEK cells
Diverse KOR agonists were tested for ERK1/2 phosphorylation in HEK cells using incell western blotting. Figure 4.1 shows representative dose-response curves, with potency and
maximal efficacy values as averages of 3 replicates per experiment, as well as the LogRAiERK
value comparing the activity of each ligand to the reference ligand U69,593. In the case of very
low intrinsic activity, compounds were tested as antagonists against a steady concentration of the
reference agonist (300nM U69,593) and that data was used to calculate the LogRAiERK value
(Figure 4.2).
Within the class of naturally-occurring compounds and their derivatives, both Salvinorin
A and mesyl salvinorin B had increased potency and maximum efficacy for ERK1/2
phosphorylation compared to the reference agonist U69,593, shown in black on every graph.
U69,593 had an EC50 of 113.9nM in this assay, and salvinorin A and mesyl salvinorin B had
EC50s of 20.3 and 37.3nM, respectively (Figure 4.1 A). Dynorphin A(1-17), however, had
decreased activity with respect to the reference agonist with a potency of 710nM.
Generally, the morphinan compounds had very little activity for ERK1/2
phosphorylation, and buprenorphine was able to block U69,593-induced ERK1/2
phosphorylation (Figure 4.1 B, Figure 4.2). The exception in this structural class was again
nalfurafine, which had comparable activity to the reference agonist U69,593. The arylacetamide
compounds, which are structurally similar to the reference agonist (Figure 3.1), had comparable
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activity as well. The exception in this structural class was the compound GR89,696, which had
increased potency and maximal efficacy compared to U69,593 with the lowest EC50 tested in this
assay of 8.7nM (Figure 4.1 C).
The quinoxaline WMS 0611 had more activity than the structurally-similar WMS 0610 in
this assay (Figure 4.1 D). Similarly, the diphenethylamine compounds had divergent activities
(Figure 4.1 E). Both the quinoxaline and diphenethylamine classes of compounds had less
activity overall than the reference agonist U69,593, and several of the diphenethylamine
compounds were able to antagonist U69,593-induced ERK1/2 phosphorylation (Figure 4.2).
These data were collected from in-cell western blots in 96-well plates (Figure 4.3 A), and
while we were unable to use U2OS cells for these full dose-response curves, single-concentration
data from regular western blots suggested that levels of ERK1/2 phosphorylation were similar
for U2OS and HEK cells (Figure 4.3 B).
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Figure 4.1. ERK1/2 phosphorylation by KOR ligands. Figures are arranged by structural
class: (A) the endogenous ligand dynorphin A (1-17), the natural product salvinorin A and
derivative mesyl salvinorin B, (B) morphinan compounds, (C) arylacetamide compounds, (D)
quinoxaline compounds and (E) diphenethylamine compounds. All dose-response curves were
normalized to the maximal U69,593 response from a concurrent sample of 10µM U69,593.
Average EC50 and Emax values are represented as averages of 4 replicates per experiment (±SD).
LogRAi values were estimated from these average EC50 and Emax values. For compounds with
low intrinsic activity data from the antagonist curves were fit to the operational model of partial
agonism to calculate LogRAi values (*). Dose-response curves are shown with a representative
U69,593 dose-response curve, in black on each graph. U69,593 stimulation was between 160 and
250% above normalized baseline, and all cells were incubated with compound for 20 minutes.
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Figure 4.2. Blockade of U69,593-induced ERK1/2 phosphorylation by KOR ligands
Compounds with low Emax values were tested as antagonists to block ERK1/2 phosphorylation by
300nM U69,593. Maximum inhibition values were calculated as the percentage of 300nM
U69,593 response. IC50 and Max inhibition values are represented as averages of 4 replicates
per experiment (±SD).
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Figure 4.3. ERK1/2 phosphorylation in different cell lines and representative in-cell
western. (A) A representative in-cell western blot in HEK293 cells, shown here in black and
white. (B) Either HEK293 or DiscoverX U2OS cells were treated with 20µM ligand and levels
of phosphorylated ERK1/2 were normalized to GAPDH expression and expressed as a percent of
concurrent 10µM U69,593 activation. U69,593 stimulation was 160-250% of normalized
baseline. U2OS data is from in-cell western blots with n = 4 replicates per experiment, and
HEK293 data is from western blots with n=3 replicates per compound per experiment.
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4.1.2 Quantifying the relationship between ERK1/2 activation and other signaling
pathways with intrinsic relative activity metric
In order to quantify each compound’s activity relative to the reference agonist U69,593 in
this assay, we calculated the LogRAiERK value, as described in Section 1.1.2. These LogRAiERK
values were then compared to the LogRAiG value and LogRAiArr values for each compound,
giving measurements of “bias” between these pathways: DLogRAiG-ERK = LogRAiG LogRAiERK (Figure 4.4) and DLogRAiArr-ERK = LogRAiArr - LogRAiERK (Figure 4.5).
Overall, the ΔLogRAiG-ERK were positive, indicating more G-protein signaling than
ERK1/2 signaling compared to the reference agonist U69,593. Exceptions to this were the
salvinorin-based compounds, as well as nalfurafine, U50,488 and several diphenethylamine
compounds that had ΔLogRAiG-ERK values close to 0 (Figure 4.4).
ΔLogRAiArr-ERK values, on the other hand, were mixed. Some compounds, such as the
endogenous peptide agonist dynorphin A(1-17) had more arrestin signaling than ERK signaling
compared to the reference agonist, indicated by its positive ΔLogRAiArr-ERK value (Figure 4.5).
Other compounds, like the majority of the morphinans, had negative ΔLogRAiArr-ERK values,
indicating more ERK signaling than arrestin signaling compared to the reference agonist in this
system (Figure 4.5).
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Figure 4.4. DLogRAi measurements between G-protein binding and ERK1/2
phosphorylation for KOR ligands
The DLogRAiG-ERK (LogRAiG – LogRAiERK) values were calculated to quantify discrepancies
between G-protein activation and ERK phosphorylation for each compound compared to the
reference agonist U69,593. Positive DLogRAi values indicate more G-protein signaling
proportional to ERK1/2 phosphorylation, while negative DLogRAiG-ERK values indicate more
ERK1/2 phosphorylation compared to G-protein signaling, relative to the reference agonist
U69,593. DLogRAi values are represented as the average of N=3 experiments, ±SD. DLogRAiGERK values

were calculated using the average EC50 and Emax as described in the methods from

three separate experiments, and are shown here plus/minus combined standard deviations.
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Figure 4.5. DLogRAi measurements between b-arrestin-2 and ERK1/2 phosphorylation for
KOR ligands
The DLogRAiArr-ERK (LogRAiArr – LogRAiERK) values were calculated to quantify discrepancies
between b-arrestin-2 recruitment and ERK phosphorylation for each compound compared to the
reference agonist U69,593. Positive DLogRAi values indicate more b-arrestin-2 signaling
proportional to ERK1/2 phosphorylation, while negative DLogRAiArr-ERK values indicate more
ERK1/2 phosphorylation compared to b-arrestin-2 signaling, relative to the reference agonist
U69,593. DLogRAi values are represented as the average of N=3 experiments, ±SD. DLogRAiArrERK values

were calculated using the average EC50 and Emax as described in the methods from

three separate experiments, and are shown here plus/minus combined standard deviations.
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4.1.3 mTOR signaling pathway differentially regulated by KOR agonists
We also investigated the ability of these KOR agonists to activate the mTOR signaling
pathway at a single high concentration (10-20 µM) by western blotting for phosphorylation of the
selective downstream target Rps6 (ribosomal protein S6, Ser240/244) in DiscoverX U2OS cells
(Figure 4.6). All data is shown as the mean intensity of Rps6 staining, normalized to GAPDH and
compared to the reference agonist U69,593, with 3 replicates per experiment. A representative
western blot is shown in Figure 4.6 as well. The reference agonist U69,593 showed robust
phosphorylation of Rps6, similar to the serum positive control for mTOR activation. KORselectivity was tested by blocking Rps6 phosphorylation with norBNI co-treatment, and mTORselectivity was tested by inhibiting Rps6 phosphorylation with Torin1. LY2444296 and norBNI,
both antagonists at the KOR, were used as negative controls and showed very low levels of Rps6
phosphorylation on their own (Figure 4.6). Almost all agonists tested showed at least 50% of
maximum U69,593 Rps6 phosphorylation. Even lower-efficacy agonists in other assays, such as
the morphinans naltrexone and buprenorphine, showed robust Rps6 phosphorylation in these
western blots (Figure 4.6).

72

250

A

Morphinans

Arylacetamides

Diphenethylamines

% of max U69,593

200
150
100
50
0

-1
7)
N
al fine
tr
e
N xon
al
m e
N efe
al
n
B
up bup e
h
re
no ine
rp
hi
U ne
50
U ,488
62
,0
G 66E
R
89
IC ,69
I2
6
04
44
8
B
PH
M
C A
B
P
M HA
C
PP
H
A
H
S6
66
3G
1
3G
no 2
LY rB
24 NI
44
29
6

N

al

fu

ra

(1

,5

D

yn

or

ph

10

in

A

69
U

%

Se

ru

m

93

-50

B
37kD
32kD

GAPDH
Rps6-P
10µM
U69,593

20µM
MCBPHA

Vehicle

MCBPHA
+ norBNI

Figure 4.6. Rps6 phosphorylation by KOR ligands
Rps6 phosphorylation (Ser240/244) was quantified at a high concentration (10-20uM) of each
compound (A) and normalized to the maximum Rps6 phosphorylation by U69,593. All signal
was normalized to GAPDH expression. Data are presented as averages of 3 replicates per
experiment, with standard deviation error bars. U69,593 stimulation was between 100-200% of
normalized baseline. (B) Representative western blot, with 3 replicates per condition, probed for
GAPDH (37 kD) and phosphorylated Rps6 (ribosomal protein S6, Ser240/244 – 32 kD).
4.1.4 Discussion
Here, we have systematically tested a diverse set of ligands for their ERK1/2 and mTOR
activation and compared their activity in these pathways to their activity in the early GPCR
signaling pathways (G-protein and b-arrestin). The differential activation of all of these signaling
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pathways is known to be dependent on what components are available in the cell, and therefore
cell line or tissue tested. While the G-protein, b-arrestin and mTOR assays were all done in the
DiscoverX U2OS cell lines (expressing human KOR) for comparison, these cells did not adhere
to the plates used for the ERK1/2 phosphorylation assay. Instead, HEK cells, expressing a
FLAG-tagged mouse KOR were used for this assay, and therefore these studies are limited by
the fact that these assays were done in different cell lines that express KORs of different species.
Both HEK and U2OS cell lines showed a single peak of ERK1/2 phosphorylation in the first 20
minutes of treatment, however, and this early-phase peak phosphorylation was used for all
studies. Phosphorylated ERK1/2 was comparable for compounds that were tested at single
concentrations in both cell lines (Figure 4.3).
Dynorphin A (1-17) showed significantly less ERK1/2 phosphorylation compared to the
reference agonist U69,593 (Figure 4.1 A). In addition to its G-protein over arrestin bias, this
suggests that dynorphin A(1-17) may activate the KOR differently than many of the synthetic
agonists tested. A recent study has shown that there can be dramatic differences in the
physiological response of the MOR between peptide and synthetic agonists,63 and our data
suggest that the peptide dynorphin A(1-17) might also lead to differential signaling outcomes
compared to synthetic KOR agonists. This is an important consideration for therapeutic
development, which may rely on data from endogenous activation to establish the desired
therapeutic effect. Salvinorin A and mesyl salvinorin B, on the other hand, showed uniquely
robust ERK1/2 phosphorylation (Figure 4.1 A), that could potentially contribute to their unique
downstream behavioral profiles.95
When the activity of these compounds in the ERK1/2 phosphorylation assay was
compared to their activity in the G-protein and b-arrestin-2 assays, the many non-zero
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ΔLogRAiG-ERK and ΔLogRAiArr-ERK values overall (Figure 4.4 and Figure 4.5) indicated that
ERK1/2 phosphorylation is not directly or uniquely downstream of just one of these other
pathways. Overall positive ΔLogRAiG-ERK values (Figure 4.4) indicated again that U69,593 may
uniquely activate ERK1/2 phosphorylation compared to G-protein activation, and demonstrated
further that our system is very sensitive to G-protein activation by other compounds. The smaller
ΔLogRAiG-ERK values for salvinorin A and mesyl sal B (Figure 4.4) indicated that G-protein
signaling may be related to ERK1/2 phosphorylation for this structural class of compounds at
this timepoint, consistent with previous work demonstrating that early-phase ERK1/2
phosphorylation by the KOR is G-protein mediated.96 This is also consistent with a study
showing that both ERK1/2 phosphorylation and Gαi activation are necessary for salvinorin A
and mesyl salvinorin B action on dopamine transporter activity.79 However, it is clear that other
factors contribute to ERK1/2 phosphorylation downstream of the KOR as this is not consistent
across structural classes.
The original study of triazole compounds demonstrated that agonist structure can impact
ERK1/2 phosphorylation downstream of the KOR independently from G-protein / arrestin bias.62
Additionally, studies have shown that many of the downstream signaling dynamics of both Gprotein and arrestin pathways are complex and interacting.97 These data support the idea that one
or both early signaling pathways likely contribute to KOR-induced ERK1/2 phosphorylation, and
that ERK1/2 phosphorylation could be mediated differently across structurally diverse agonists at
this timepoint. It is not ideal to compare between cell lines because many signaling events are
context-dependent, however, and future studies of many agonists in a single cellular context are
needed. These data support that ERK1/2 phosphorylation should be considered independently in
studies of KOR signaling.
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Unlike ERK1/2 phosphorylation, mTOR pathway activation has only recently been
implicated in KOR signaling. Recent studies have demonstrated that the mTOR signaling
pathway may be involved in mediating aversion caused by KOR agonists.36,39 These studies
characterized several KOR agonists, including U50,488 and MCBPHA (HS665 in Liu, et al.
2018), as activators of the mTOR pathway in the mouse striatum and cortex. They found that
other KOR agonists, such as HS666 and nalfurafine, did not activate the mTOR pathway in these
regions at the doses tested. They also found that mTOR activation tracked with KOR-mediated
aversion caused by these compounds – U50,488 and MCBPHA caused aversion at the doses that
also caused mTOR activation, while nalfurafine and HS666 were not aversive and did not cause
mTOR activation at the doses tested. Further, they found that blocking mTOR activation was
able to block U50,488-mediated conditioned-place aversion.
In our experiments, robust Rps6 phosphorylation (at least 50% of maximum U69,593
stimulation) was caused by the vast majority of agonists tested (Figure 4.6). Compounds such as
nalfurafine, which did not show mTOR activation in previous studies at lower concentrations,
were still robust activators of the pathway in this experiment. The differences between this study,
in which all KOR agonists tested activated the mTOR pathway, and the previous study in which
only a subset of KOR agonists activated the pathway, are likely due in part to differences in both
tissue tested and concentrations used.
Similarly to ERK1/2 phosphorylation, there are discrepancies between the early signaling
pathways (G-protein and arrestin) and Rps6 phosphorylation in this system. Agonists that had
very little β-arrestin-2 recruitment, such as nalmefene and naltrexone (Figure 3.2 B), still showed
robust Rps6 phosphorylation (Figure 4.6), suggesting that G-protein activation may be more
involved than arrestin signaling in activating the mTOR pathway. The dynamics appear more
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complex than this, however, as agonists such as 3G1 and 3G2 showed 100% maximum effect for
G-protein signaling but only partial Rps6 phosphorylation (Figure 3.4 E and Figure 4.6). Full
quantitative dose-response and functional studies are needed to further elucidate the relationships
between the early signaling pathways and complex downstream mTOR activation. Overall, these
data demonstrate that diverse KOR agonists can differentially regulate both ERK1/2
phosphorylation and mTOR activation (through Rps6 phosphorylation). This indicates that
individual signaling modalities should be studied independently, and these complex downstream
pathways should not be used as proxies for initial signaling events, as has been done in some
studies of G-protein and arrestin bias.35 These downstream signaling pathways are likely the
consequence of complex crosstalk between pathways, including G-protein, b-arrestin-2, and
potentially additional signaling pathways.

4.2 Identification of novel KOR-signaling pathways
Data from other studies, as well as our ERK1/2 and mTOR studies in Chapter 2.1, have
indicated that there are signaling pathways that can be differentially regulated by agonists at the
KOR in addition to the well-characterized G-protein and arrestin pathways.36,62 While it is
possible that these pathways are affected by events further downstream of the receptor, it is also
possible that there are additional receptor-proximal signaling partners that are differentially
regulated directly by changes in receptor conformation caused by specific agonists (Figure 4.7).
In this case, these other signaling partners could be involved in KOR-mediated behaviors and
used to further refine a desired ligand “bias” profile for therapeutically-beneficial downstream
effects.
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Here, we aimed to identify novel protein binding partners of the KOR. First, we optimized
an immunoprecipitation protocol for a FLAG-tagged KOR. Then, we compared protein-binding
partners of the KOR under different signaling conditions to identify differentially-regulated
proteins.

Figure 4.7. Effect of biased agonists on receptor-protein interactions
4.2.1 Validation of KOR immunoprecipitation
First, KOR-FLAG proteins and interacting protein binding partners were
immunoprecipitated from HEK cells to optimize the immunoprecipitation protocol using M2agarose beads. The sample eluted from the beads was prepared via trypsin digestion and proteins
were identified using LC-MS/MS and FLAG-KOR proteins were additionally identified by
western blot. We found that KOR-FLAG proteins were enriched in the immunoprecipitated
sample relative to total protein, shown both through western blotting (Figure 4.8) and later LCMS/MS analysis. While only 2 KOR peptides were reliably identified in the immunoprecipitated
samples, this is consistent with previous reports of KOR immunoprecipitations, likely due to
poor solubility and interference from membrane components. Overall, these data indicate that the
KOR was successfully immunoprecipitated.
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To identify which proteins were interacting with the KOR, protein hits from the LC-MS/MS
were analyzed by MaxQuant software and subsequently filtered, as described below. Over 1000
proteins were identified in the experiment. First, these were filtered for their posterior error
probability (PEP) score, which is the probability that the identification of any given peptide is
incorrect.73 All proteins with peptide PEP scores of greater than 10-4 were eliminated, as well as
proteins that only had 1 identified peptide. In the optimized immunoprecipitation, this left 947
identified proteins. A significant number of these proteins were related to protein trafficking,
including ER and Golgi-bound proteins. This indicated that much of the KOR-FLAG may not
have been at the membrane surface, and that the proteins identified may have been unrelated to
KOR signaling at the membrane. This is not unusual for membrane-bound proteins. However, a
large number of signaling and receptor-related proteins were also identified (Table 4.1). Proteins
that were expected to interact with the KOR, such as G-proteins and ubiquitin-related proteins,
were identified, as well as proteins that have previously been shown to interact with other opioid
receptors in previous yeast-2-hybrid experiments.98

Figure 4.8. FLAG-KOR proteins enriched in
immunoprecipitation
FLAG-KOR proteins were immunoprecipitated and
run on SDS-PAGE gel from both two different cell
lysates (H and L). Lysate and eluted samples were
stained for total protein using REVERT total protein
stain and (grey) and FLAG (green) expression,
showing enrichment of the FLAG-KOR protein in
the eluted fraction.
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Protein Identity
OPRK1, opioid receptor, kappa 1
G-proteins (shown to be involved in KOR signaling)
GNAI3, guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3
GNAI2, G protein subunit alpha i2
GNB1, guanine nucleotide binding protein (G protein), beta polypeptide 1
GNB2, guanine nucleotide binding protein (G protein), beta polypeptide 2
GNB2L1, guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1
MAPK-related proteins (shown to be involved in KOR signaling)
TAB1, TGF-beta activated kinase 1/MAP3K7 binding protein 1
MAP3K7, mitogen-activated protein kinase kinase kinase 7
TAB3, TGF-beta activated kinase 1/MAP3K7 binding protein 3
Ubiquitin-related (shown to interact with KOR)
UBAP2L, ubiquitin associated protein 2 like
RNF20, ring finger protein 20, E3 ubiquitin protein ligase
USP10, ubiquitin specific peptidase 10
Ribophorin1 (shown to interact with KOR) and Ribophorin2
RPN1, ribophorin I
RPN2, ribophorin II
Calmodulin (shown to interact with MOR and DOR)
CALM2, calmodulin 2
Calnexin (shown to interact with DOR)
CANX, calnexin
Filamin A (shown to interact with MOR) and Filamin B
FLNA, filamin A
FLNB, filamin B
Synaptophysin (shown to interact with MOR)
SYPL1, synaptophysin-like 1

LogPEP
-12.7

Total peptides
4

-52.4
-42.7
-77.5
-65.3
-22.7

8
2
12
3
5

-275.7
-195.8
-63.3

61
39
9

-163.9
-15
-9.1

23
2
2

-205.5
-67.5

34
12

-99

20

-92.4

5

-2077.7
-1201.8

459
148

-14.1

2

Table 4.1. Signaling and receptor-related proteins identified in co-immunoprecipitation
with FLAG-KOR. Proteins that co-immunoprecipitated with FLAG-KOR were identified by
LC-MS/MS and data analyzed using MaxQuant software. Proteins with previously demonstrated
interactions with opioid receptors were based on previous experiments reviewed in Georgoussi
et. al. 2012.98

4.2.2 SILAC preparation of cells for investigation of activation-specific interactions
After optimizing the immunoprecipitation protocol, we used a SILAC (stable isotopelabeled amino acids in cell culture) approach to compare protein-binding partners under different
signaling conditions (Figure 4.9). Cells were grown with heavy (15N lysine and arginine) amino
acid media and treated with vehicle, alongside cells grown with regular (light) amino acid media
that were treated with 10-20µM of a KOR agonist. Cells were then lysed, membranes isolated
and solubilized and equal amounts of protein lysate from the vehicle (heavy) and agonist-treated
(light) samples were mixed for immunoprecipitations. Protein-receptor interactions were then
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identified using LC-MS/MS, and filtered for quality by PEP score and number of peptide.
Additionally, protein identities were matched against a database of commonly-identified proteins
in similar protocols, to eliminate proteins that are incredibly abundant in the cell and likely to
immunoprecipitate with many different bait proteins.99

Figure 4.9. SILAC approach for identifying differences in receptor-protein interactions
with KOR agonist treatment

For each protein, an intensity ratio was calculated, comparing the amount of that protein in
the light sample (treated with agonist) to the amount of that protein in the heavy sample (treated
with vehicle). An intensity ratio of 0.5 indicated no change in intensity between the vehicle and
treated cells. An intensity ratio of >0.5 indicated increased intensity of that protein in the agonisttreated cells, and an intensity ratio of <0.5 indicates decreased intensity of that protein in the
agonist-treated cells. The range of intensity ratios was not very large for the proteins identified
(0.6-0.4), suggesting that there were not large fluctuations in receptor-protein interactions with
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agonist treatment overall. The intensity ratios were consistent across two replicates, however
(Figure 4.10), suggesting that these small fluctuations in intensity ratio may be biologically
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Figure 4.10. Intensity ratios consistent across SILAC replicates
Intensity ratios were calculated as the [Intensity in Light Sample / (Intensity in Light Sample +
Intensity in Heavy Sample)]. An intensity ratio of 0.5 indicates equal intensity in both the
vehicle-treated (Heavy) and KOR agonist-treated (Light) sample. Replicate data are shown for
10 proteins that were reliably identified across several different experiments, with filtering as
described in the text and methods. In this case, both replicates compared 10µM U69,593 and
vehicle treatments.

4.2.3 Ligand identity affects activation-specific interactions
Intensity ratios for many proteins were then compared for different agonist treatments
including the reference agonist U69,593, the G-protein biased diphenethylamine agonist
MCBPHA or the extremely G-protein biased diphenethylamine agonist BPHA (Figure 4.11). In
each graph, a dot represents a single protein that was identified in all experiments. The intensity
ratios from the different agonist treatments for each protein were then plotted against each other.
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Intensity ratios for the proteins in the sample treated with U69,593 did not correlate with the
intensity ratios for the same proteins in samples treated with either MCBPHA or BPHA (Figure
4.11 A, B). Intensity ratios for proteins in the sample treated with MCBPHA did show a
significant correlation with the intensity ratios for the same proteins in the sample treated with
BPHA (Figure 4.11 C).

Figure 4.11. Intensity ratios for proteins identified in co-immunoprecipitations after
different treatment conditions
Intensity ratios were calculated for protein-receptor interactions when vehicle-treated cell were
compared with U69,593-treated cells, BPHA-treated cells and MCBPHA-treated cells and
intensity ratios compared here. Each dot represents an individual protein that interacted with the
KOR under all conditions tested. There was no significant correlation between the U69,593treated intensity ratios and either (A) MCBPHA or (B) BPHA-treated intensity ratios. (C) There
was a significant correlation (Pearson r = 0.41, p<0.001) between the MCBPHA and BPHAtreated intensity ratios.
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Table 4.2 shows the intensity ratios for 10 of the top proteins in all 3 treatment conditions.
Four of the proteins are involved in protein folding and trafficking, suggesting that many of the
candidate proteins identified may be background noise. Interestingly, 2 of these top 10 proteins
are involved in 14-3-3 signaling (TRIM25 and STRAP).

Table 4.2. Intensity ratios for top 10 proteins identified in all co-immunoprecipitations
Descriptions of the top 10 protein-receptor interactions in all treatment conditions (based on
filtering criteria described in text and methods) and intensity ratios for different treatment
conditions. Proteins marked with an asterisk(*) were involved in membrane-protein trafficking
and processing.

4.2.4 14-3-3 localization affected by KOR activation
14-3-3 proteins are ubiquitously expressed signaling scaffolds, that have been shown to play
an important role in GPCR signaling, and to interact with the KOR under different
conditions.100,101 To assess the effect of KOR activation on 14-3-3 signaling, we looked at 14-3-3
localization in HEK cells expressing a GFP-tagged KOR following treatment with U69,593
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(Figure 4.12). When cells were treated with vehicle, in this case serum-free DMEM media, 14-33 was localized to the cytoplasm of the cell. After 1 hour treatment with 10uM of the full,
unbiased KOR agonist U69,593, however, a portion of the 14-3-3 protein was localized to the
nucleus of the cell (Figure 4.12 B).
To investigate this further, high-throughput imaging of 200-300 nuclei per sample indicated
a dose-dependent increase in 14-3-3 nuclear localization with increasing concentrations of
U69,593 (Figure 4.13). This effect was partially blocked by co-treatment of the cells with the
KOR-selective antagonist norBNI, suggesting that this effect is mediated by KOR (Figure 4.13).
While one-way ANOVA revealed a significant effect of treatment (F(4,2098) = 28.47), the
overall effect size was small, with only 5% of the variation coming from different treatment
conditions (h2 = 0.05).

Figure 4.12. 14-3-3 proteins localize to the nucleus after KOR activation
HEK cells expressing a GFP-tagged KOR were stained for pan-14-3-3 expression (grey) and
imaged with confocal microscopy. Cells were treated with (A) vehicle and (B) 10µM U69,593.
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Figure 4.13. U69,593 treatment causes dosedependent nuclear localization of 14-3-3
HEK cells expressing GFP-tagged KOR were plated in
96-well plates, treated with varying doses of the agonist
U69,593 and stained with DAPI and for pan-14-3-3
localization using wide-field microscopy. Intensity of
14-3-3 staining in the nucleus was quantified by colocalization with DAPI staining. Data are represented as
the mean of 600-1200 nuclei from two samples (±SD).

4.2.5 Discussion
The identification of additional pathways directly involved in GPCR signaling has been
historically difficult, due to the technical complexity of biochemical experiments with
membrane-bound proteins. Previously, work has been done to identify phosphorylated proteins
that were differentially regulated by structurally diverse GPCR agonists (including the
KOR),36,102 and as well as to identify proteins that differentially interact with arrestins after
agonist activation.103 More recently, innovative methods for labeling proteins in close proximity
to opioid receptors after agonist activation have identified potential novel protein-receptor
interactions as well.104 Here, we attempted to directly identify novel protein-receptor interactions
through immunoprecipitation and mass spectrometry, using an isotope-labeling approach (Figure
4.9).
First, we validated our immunoprecipitation by comparing the proteins that we identified
in our sample to a list of proteins that had previously been identified as interactors with opioid
86

receptors (Table 4.1). Combined with the clear enrichment of FLAG-KOR protein in our eluted
sample (Figure 4.8), these data suggested that our immunoprecipitation likely included proteins
that interacted with the KOR at the membrane where it could be activated by agonists. To
identify proteins specifically involved in signaling, we compared protein-receptor interactions
when the cells were treated with vehicle to interactions when the cells were treated with a KOR
agonist using stable-isotopes to label amino acids in the different cell populations (Figure 4.9).
With the intensity ratios calculated from these samples, we examined both the larger
patterns of receptor-protein interaction as well as specific candidate proteins. When comparing
the intensity ratios of all of the proteins identified, we found that the structurally similar
diphenethylamine agonists had correlated intensity ratios, while U69,593 did not (Figure 4.11).
This suggests that the intensity ratios for proteins, which is a measure of the change in binding
interaction upon KOR activation, was related to the ligand identity, and many proteins could be
differentially regulated by agonist identity. Additional studies with diverse agonists could help to
identify relationships between intensity ratios overall and any specific feature of agonists - such
as G-protein or arrestin signaling, a certain structural feature, or even a downstream behavior.
We then examined specific proteins that interacted with the KOR for candidate signaling
pathways that may be involved in KOR signaling. Of the 10 most abundant proteins that were
identified in all samples (after filtering as described in the methods), two were involved in 14-3-3
signaling (Table 4.2). We found a weak, but significant, dose-dependent increase in 14-3-3
nuclear localization following treatment of cells with U69,593, and this was partially blocked by
the KOR-selective antagonist norBNI (Figure 4.12, Figure 4.13). These experiments used a pan14-3-3 antibody, however, so further investigation into the subtypes of 14-3-3 involved in KOR
signaling are necessary. 14-3-3 proteins are ubiquitously and abundantly expressed, actually
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comprising 1% of all protein in the brain.105 For this reason, 14-3-3 proteins themselves often
emerge as hits in high-throughput protein expression screens like the one here. Despite this, the
imaging data, along with previous data describing 14-3-3 and KOR interactions, suggests that
14-3-3 may be involved in KOR signaling in a meaningful way that involves nuclear
localization.
It has been shown recently that 14-3-3 signaling can be differentially regulated
downstream of GPCRs, depending on agonist identity.100 Further investigation into the
regulation of 14-3-3 by diverse KOR agonists, particularly agonists that are known to be biased
for other pathways, will be important for elucidating the role that 14-3-3 proteins play in
regulating the signaling or trafficking of the KOR. Additionally, the majority of GPCR-14-3-3
research has focused on the role of 14-3-3 as a scaffolding protein. Further research into the role
of 14-3-3 in the nucleus following GPCR activation is needed.
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CHAPTER 5. IN VIVO EFFECTS OF DIFFERENT KOR AGONISTS

5.1 Effect of diverse KOR agonists on prolactin release in mice
In addition to mediating the effects of drugs of abuse, the dopaminergic effects
downstream of opioid receptors regulate other processes in the brain and body. For example, the
release of the hormone prolactin is under inhibitory control by dopamine, from neurons
projecting from the hypothalamus to the pituitary. Prolactin is known for its involvement in
pregnancy and lactation, however it also plays an important part in the stress response.106 It has
been shown that activation of the KOR by dynorphin peptides following stress,107,108 or by
exogenous KOR agonists, 109,110 leads to an increase in prolactin levels, mediated by dopamine in
this tuberoinfundibular dopaminergic system.
Work from Butelman, et. al. has shown that levels of prolactin can be used as a
quantitative biomarker of KOR activation,111 and prolactin levels have been used in rodents,86
non-human primates112 and humans32 to investigate KOR activity in vivo. In this study, we
investigated the effects of several, structurally diverse KOR agonists on the release of prolactin
in mice.

5.1.1 Prolactin release caused by diverse KOR agonists
For all experiments, mice were injected intraperitoneally with compound or vehicle and
then sacrificed 30 minutes later (unless otherwise noted) and trunk blood was collected. Prolactin
levels in the serum were measured by sandwich ELISA. We found an increase in serum prolactin
after treatment with the full, unbiased arylacetamide agonist U50,488, and that this increase was
blocked, at least in part, by a KOR-selective dose of the antagonist LY2444296 (Figure 5.1). The
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diphenethylamine compounds BPHA, MCBPHA and MCPPHA all caused significant prolactin
release at doses of 30mg/kg (Figure 5.1), and these effects were blocked by the antagonist
LY2444296.
We also examined the morphinan compound nalfurafine, that had a unique signaling
profile in vitro (Figure 3.2, Figure 3.3). A dose of 10µg/kg nalfurafine caused significant
prolactin release after 30 minutes compared to saline treatment (Figure 5.2 A). This effect was
blocked by the KOR-selective dose of LY2444296, indicating that this nalfurafine-induced
prolactin release was mediated by the KOR (Figure 5.2 A). The lower dose of 3µg/kg nalfurafine
caused significant prolactin release, however there was no effect of the doses lower than this (1
and 0.3µg/kg nalfurafine) (Figure 5.2 B). Levels of prolactin in the serum remained elevated for
at least 60 minutes after intraperitoneal injection of 10µg/kg nalfurafine, but returned to normal
by 120 minutes (Figure 5.2 C).
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Figure 5.1. Prolactin release caused by U50,488, and diphenethylamine compounds. Mice
were pretreated with either vehicle or 3mg/kg LY2444296 15 minutes before an injection of
30mg/kg U50,488, MCBPHA, BPHA or MCPPHA. Serum prolactin levels were measured in
samples taken 30 minutes after the second injection. * = p < 0.05, *** = p < 0.0005, **** = p <
0.0001, by one-way ANOVA followed by followed by Dunnett’s multiple comparison test
compared vehicle-saline control group. Each experiment was tested independently for
significance.
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Figure 5.2. Prolactin release caused by the morphinan compound nalfurafine. A. Mice
received an injection intraperitoneally of either LY2444296 or vehicle 15 minutes before an
injection of 10µg/kg nalfurafine. Samples were collected 30 minutes after the second injection.
Two-way ANOVA (LY244296 pretreatment x Nalfurafine treatment) revealed a significant
effect of both LY2444296 pretreatment (F(1,30) = 86.75, p < 0.0001), Nalfurafine treatment
(F(1,30) = 115.3, p < 0.0001) and their interaction (F(1,30) = 96.36, p < 0.0001). Newman-Keuls
multiple comparison test revealed significant differences between Vehicle/Nalfurafine group and
all other groups (****p<0.0001). B. Serum prolactin levels were measured in samples taken 30
minutes after intraperitoneal injection of varying doses of nalfurafine. One-way ANOVA
revealed a significant effect of Treatment (F(4,35) = 9.67, p < 0.0001). Dunnett’s multiple
comparison test revealed significant differences between nalfurafine or U50,488 treated groups
and saline-treated control group (*p < 0.05, ***p < 0.0005). C. Serum prolactin levels were
measured in samples taken 15-120 minutes after intraperitoneal injection of 10µg/kg nalfurafine
or saline. Two-way ANOVA (Treatment x Time) revealed a significant effect of Treatment
(F(1,56) = 62.56, p < 0.0001), Time (F(3,56) = 7.24, p < 0.0005) and their interaction (F(3,56) =
5.73, p < 0.005). Newman-Keul’s multiple comparison at each timepoint revealed significant
differences between saline and nalfurafine-treated groups (**p < 0.005, ***p < 0.0005, ****p <
0.0001).
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5.1.2 Discussion
All compounds tested were compared to a concurrently-run vehicle or saline-treated
group, in order to control for the variation in prolactin levels caused by handling and stress
across animal groups. All of the compounds tested caused an increase in serum prolactin,
including the extremely G-protein biased agonist BPHA (Figure 5.1). This increase in prolactin
was blocked by the KOR-selective dose of the antagonist LY2444296 (Figure 5.1). BPHA
showed no measurable arrestin recruitment in the PathHunter DiscoverX assay, and was able to
block arrestin recruitment caused by the full agonist U69,593 (Figure 3.2 E, Figure 3.3 B). This
suggests that arrestin recruitment is not required for prolactin release, and potentially not
required for the effects of KOR activation on dopamine levels, at least in the tuberoinfundibular
dopamine system. Additional research into the mechanism of KOR modulation of dopamine tone
in different dopaminergic systems will be important for understanding more about prolactin
release as a biomarker for KOR activation, as well as for understanding more about KOR actions
on dopamine levels in general.

5.2 Effects of KOR agonists on sedative and aversive side effects in mice
KOR agonists have also been shown to cause side effects such as sedation and aversion
in human and animal models that have stalled the development of KOR agonists as therapeutics.
To avoid these negative side effects, there has been a focus on the development of biased
agonists at the KOR, particularly with more G-protein than arrestin activity.50 Several studies of
G-protein biased agonists, along with the work that is presented in Chapter 3, suggest that
arrestin recruitment is required for KOR-mediated sedation.34,51,52 It is unclear, however, if this
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signaling pathway is related to the aversive or dysphoric side effects of KOR agonists. Several of
the studies of G-protein biased agonists have shown that they cause antinociception or
antipruritus without causing dysphoria or anhedonia,51,52 and mechanistic studies have shown
that arrestin-dependent p38 phosphorylation is needed for this KOR-mediated aversion.59
However, recent studies have also suggested that the mTOR pathway is necessary for KORmediated aversion, but not sedation, suggesting that these negative side effects could be
mediated by different signaling pathways.36,39 Here, we examined the effect of BPHA, an
extremely G-protein biased agonist with no measurable arrestin recruitment on conditioned-place
aversion.
Data from previous human studies are also essential for establishing the translational
potential of KOR agonists. Interestingly, there is only one selective KOR agonist that is currently
in clinical use in humans. Nalfurafine was approved to treat pruritus in Japan in 2009, and postmarketing studies of over 3,000 patients have shown very few KOR-associated side effects.37 In
rodent studies, nalfurafine has been shown to cause antipruritic and antinociceptive effects at
doses that do not cause sedation or aversion, while traditional KOR agonists like U50,488 and
salvinorin A caused both the therapeutic and side effects at similar doses.35,78,113 There are fewer
studies, however, comparing the effective doses of KOR agonists in modulating drug-related
behaviors compared to negative side effects. Here, we also examined the effects varying doses of
nalfurafine on KOR-mediated sedation to compare to other in vivo effects such as prolactin
release (Subsection 5.1) and the modulation of cocaine-induced behaviors (Subsection 5.3).
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5.2.1 Sedation caused by KOR agonists measured by rotarod assay
Multiple doses of the arylacetamide compound U50488 and the morphinan compound
nalfurafine were tested for rotarod sedation. As noted in Chapter 3.2, high doses of both of these
compounds caused very robust sedation in the rotarod assay at 30 minutes post-injection (Figure
3.8). This maximally effective dose of 30mg/kg U50,488 was sedative almost immediately after
injection, with rotarod performance beginning to recover at 60 minutes post-injection (Figure
5.3). 10mg/kg U50,488 was sedative compared to a saline control group only 30 minutes postinjection, while mice treated with 3mg/kg U50,488 were not impaired in the rotarod assay at any
timepoint tested (Figure 5.3)
100µg/kg nalfurafine caused significant sedation, as measured by the rotarod assay,
compared to a saline injected group (Figure 5.4 A). This effect was completely blocked by a
KOR-selective dose of 3mg/kg LY2444296, indicating that this nalfurafine-induced sedation was
mediated by the KOR (Figure 5.4 A). Higher doses of 300µg/kg and 3mg/kg nalfurafine caused
significant sedation in this assay; mice performed at approximately 13% of their baseline
performance after 30 minutes and the effect was still significant after 60 minutes (Figure 5.4 B).
Mice had fully recovered after 24 hours, however. A dose of 30µg/kg nalfurafine had
comparable sedation to a moderate dose of 10mg/kg U50,488 (Figure 5.4 C). At the doses of
3µg/kg and 10µg/kg however, there was no significant effect on rotarod sedation compared to
saline injections at the same timepoint (Figure 5.4 C).
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Figure 5.3 Rotarod sedation caused by U50,488. Mice were treated with varying doses of
U50,488 or saline and rotarod performance was measured at selected timepoints after injection,
and compared to baseline. Two-way ANOVA (Treatment x Time) revealed a significant effect of
Treatment (F(3,24) = 13.77, p < 0.0001), Time (F(2,48) = 7.05, p , 0.005) and their interaction
(F(6,48) = 3.03, p < 0.05). Dunnett’s multiple comparison test at each timepoint revealed
significant differences between U50,488 and Saline treated groups (**p < 0.005, ****p <
0.0001).
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Figure 5.4. Rotarod sedation caused by nalfurafine. Rotarod performance was measured at
select timepoints after IP injection of KOR nalfurafine, or saline, and compared to baseline
rotarod performance in all experiments. A. Mice were pretreated for 15 minutes with
3mg/kgLY2444296 before injection with 100µg/kg nalfurafine. There was no effect of
LY2444296 alone on rotarod sedation (see Dunn and Reed, 2018).86 Two-way ANOVA
(Treatment x Time) revealed a significant effect of Treatment (F(2,21)=14.38, p < 0.0005), Time
(F(2,24)=7.99, p < 0.005) and their interaction (F(4,42)=2.66, p<0.05). Dunnett’s multiple
comparison test at each timepoint revealed significant differences between the Vehicle/Saline
control group and Vehicle/Nalfurafine group only (**p<0.005, ***p<0.0005). B. Two-way
ANOVA (Treatment x Time) revealed a significant effect of Treatment (F(4,31) = 48.72), p <
0.0001), Time (F(2,62) = 26.64, p < 0.0001) and their interaction (F(8,62) = 4.0, p < 0.0005).
Dunnett’s multiple comparison test at each timepoint revealed significant differences between
nalfurafine treatment groups and Saline-treated control group (**p < 0.05, *** = p < 0.0005,
**** = p < 0.0001). C. Two-way ANOVA (Treatment x Time) revealed a significant effect of
Treatment (F(4,30) = 3.38), p < 0.05) and Time (F(2,60) = 7.12, p < 0.005) but no effect of their
interaction (F(8,60) = 1.19). Dunnett’s multiple comparison test at each timepoint revealed
significant differences between nalfurafine and U50,488 treatment groups and Saline-treated
control group (**p < 0.05).
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5.2.2 Aversion caused by KOR agonists measured by place conditioning assay
For the conditioned-place aversion assay, mice were first allowed to freely explore the 3chamber apparatus and the time spent in each chamber was recorded. During conditioning
sessions, mice received an injection of vehicle or KOR agonist and were placed in the drugpaired chamber for 30 minutes. The same day, they received an injection of vehicle or KOR
agonist (opposite of AM injection) and were immediately placed in the opposite chamber for 30
minutes. Chambers had different colored walls, as well as different textured floors. The day after
all conditioning sessions were finished, mice were allowed to freely explore the 3-chamber set
up again and the time spent in each chamber was recorded. If mice spent less time in the drugpaired chamber after the conditioning sessions than they did before the conditioning sessions,
that suggested aversion to the drug-paired context, and by extension, the drug.
Several KOR agonists were tested at doses that were non-sedative. The non-sedative dose
of 3mg/kg U50,488 did not cause any difference in time spent in the drug-paired chamber
(Figure 5.5), suggesting that it was not aversive. Nalfurafine, at doses of both 3µg/kg and
10µg/kg, also did not cause any change in time spent in the drug paired chamber compared to
saline (Figure 5.6 A and B). When mice were treated with 30mg/kg of the extremely G-protein
biased diphenethylamine agonist BPHA before conditioning, however, they spent significantly
less time in the drug-paired chamber compared to the vehicle-paired chamber (Figure 5.7).
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Figure 5.5. Conditioned-place aversion with a non-sedative dose of U50,488
Mice were injected IP with 3mg/kg U50,488, and then injected with saline and placed in drugpaired chambers 15 minutes later. Mice were conditioned for 2 session (30 minutes each) in the
paired chamber, as well as 2 sessions (30 minutes each) in the opposite chamber following
injections of saline in place of drug. Data is represented as the difference in the time spent in the
paired chamber after the conditioning sessions, compared to before the conditioning sessions.
There was no effect of treatment by unpaired T-test.
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Figure 5.6 Conditioned-place aversion with non-sedative doses of nalfurafine
Mice were IP injected with 3µg/kg (A) or 10µg/kg (B) nalfurafine, and then injected with saline
and placed in drug-paired chambers 15 minutes later. Mice were conditioned for 2 session (30
minutes each) in the paired chamber, as well as 2 sessions (30 minutes each) in the opposite
chamber following injections of saline in place of drug. Data is represented as the difference in
the time spent in the paired chamber after the conditioning sessions, compared to before the
conditioning sessions. There was no effect of treatment by unpaired T-test in either experiment.
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Figure 5.7 Conditioned-place aversion caused by BPHA
Mice were conditioned for 4 sessions (30 minutes each) in a paired chamber following IP
injection of either vehicle or 30mg/kg BPHA as well as 4 sessions (30 minutes each) in the
opposite chamber following injection of vehicle. Data is represented as the difference in the time
spent in the paired chamber after the conditioning sessions, compared to before the conditioning
sessions. T-test revealed significant effect of BPHA treatment compared to vehicle (*p<0.05).

5.2.3 Discussion
Here, we found that although high doses of the full agonists U50,488 and nalfurafine
were extremely sedative, lower doses were not sedative or aversive in these assays. Low doses of
nalfurafine, such as the 3µg/kg and 10µg/kg doses tested here, have been shown to cause
antipruritic and antinociceptive effects, as well as prolactin release (Figure 5.2), suggesting that
they are still able to activate the KOR. Higher doses of nalfurafine, have been shown to be
sedative, 114,115 consistent with findings here (Figure 5.4). These data are also consistent with
previous studies demonstrating that nalfurafine is more potent for therapeutic endpoints, in this
case prolactin release, than side effects like sedation. Here, nalfurafine at 3µg/kg and 10µg/kg
caused significant prolactin release (Figure 5.2) but not sedation (Figure 5.4).
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While our CPA findings are consistent with other groups demonstrating that these doses
of nalfurafine are not aversive, a recent study found that 10µg/kg nalfurafine could potentially
increase thresholds in intracranial self-stimulation, suggesting that it could cause dysphoria,
depending on the assay used.116
Interestingly, BPHA, which is an extremely G-protein biased agonist with no measurable
arrestin activity (Figure 3.2), caused significant aversion compared to vehicle (Figure 5.3). This
suggests that arrestin recruitment may not be necessary for the aversive side effects of KOR
agonists, in the way that arrestin recruitment appears to be necessary for the sedative side effects
of KOR agonists. Recent work has shown that the mTOR signaling pathway may be important
for KOR-mediated aversion, but not sedation, and these data further support that these two
negative side effects are mediated by different signaling pathways. Further research into the
signaling mechanisms and circuits that lead to these behaviors is necessary to better understand
how to develop drugs that can activate the KOR for therapeutic purposes, while avoiding
aversive side effects.

5.3 Effect of KOR agonists on cocaine-related behaviors in mice
In addition to pain and pruritus, KOR agonists have been of particular interest in treating
cocaine and psychostimulant addiction, as KOR activation inhibits the dopamine release caused
by these drugs17 and there are currently no available treatments for these diseases. KOR agonists
have been shown to block the rewarding effects of drugs of abuse, including cocaine. Because of
its positive clinical and post-marketing data in treating pruritus, nalfurafine is of particular
interest for future clinical studies in this area. However, there are few studies that have examined
effects of nalfurafine on cocaine-related behavior or comparing nalfurafine and other KOR
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agonists head-to-head for this therapeutic effect.114,117 Here, we investigated the effects both
nalfurafine and the full KOR agonist U50,488 in two mouse models of cocaine-induced reward
at doses that did not cause sedative side effects (Figure 5.3 and Figure 5.4).

5.3.1 Effect of KOR agonists on cocaine-conditioned place preference
In a 3-chamber conditioned place preference paradigm, similar to the CPA assay in
Subsection 5.2.1, mice that were conditioned with an injection of 15mg/kg cocaine spent more
time in the drug-paired chamber after conditioning, indicating cocaine preference or reward, as
expected. When mice were pretreated for 15 minutes with a relatively low dose of 3mg/kg
U50,488 before receiving cocaine, however, this preference was attenuated (Figure 5.8). When
mice were pretreated for 15 minutes with 10µg/kg nalfurafine (Figure 5.9 A) or 3µg/kg
nalfurafine (Figure 5.9 B), conditioned-place preference for the cocaine-paired chamber was also
attenuated. These same doses of U50,488 and nalfurafine were not aversive on their own (Figure
5.5 and 5.6).
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Figure 5.8. U50,488-induced blockade of cocaine-conditioned place preference. Mice were
treated with 3mg/kg U50,488 or saline, and then 15 minutes later treated with 15mg/kg cocaine
or saline before immediately being placed in appropriate conditioning chambers for 30 minutes.
4 total conditioning sessions were done, 2 in each box, across 2 days. Two-way ANOVA
(U50,488 Pretreatment x Cocaine Treatment) revealed a significant effect of Cocaine Treatment
(F(1,36) = 5.11, p < 0.05) but no effect of U50,488 Pretreatment (F(1,36) = 1.60) or interaction
(F(1,36) = 4.07). Newman-Keuls multiple comparison test revealed significant differences
Cocaine group and all other groups (*p<0.05).
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Figure 5.9. Nalfurafine blockade of cocaine-conditioned place preference. A. Mice were
treated with 10µg/kg nalfurafine or saline, and then 15 minutes later treated with 15mg/kg
cocaine or saline before immediately being placed in appropriate conditioning chambers for 30
minutes. 4 total conditioning sessions were done, 2 in each box, across 2 days. Two-way
ANOVA (Nalfurafine Pretreatment x Cocaine Treatment) revealed significant effect of Cocaine
Treatment (F(1,32) = 22.59, p < 0.0001) but not Nalfurafine Pretreatment (F(1,32) = 1.68), as
well as a significant Cocaine x Nalfurafine interaction (F(1,32) = 9.01, p < 0.01). Post-hoc
Newman-Keuls analysis revealed significant differences between Saline/Cocaine and
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Nalfurafine/Cocaine (**p < 0.005), Nalfurafine/Saline (**p < 0.005) and Saline/Saline (***p <
0.0005) and no differences between other groups. B. Mice were treated with 3µg/kg nalfurafine
or saline, and then with 15mg/kg cocaine or saline using identical methods. Two-way ANOVA
(Nalfurafine Pretreatment x Cocaine Treatment) revealed no significant effect of Cocaine
Treatment (F(1,28) = 2.06) or Nalfurafine Pretreatment alone (F(1,28) = 1.88), however there
was a significant Cocaine x Nalfurafine interaction (F(1,24) = 5.22, p < 0.05). Post-hoc
Newman-Keuls analysis revealed significant difference between Saline/Cocaine and
Nalfurafine/Cocaine (*p<0.05).

5.3.2 Effect of KOR agonists on cocaine self-administration after acquisition
Effects of these lower doses of U50,488 and nalfurafine were tested in a model of
intravenous cocaine self-administration in mice as well. After 7 days of cocaine selfadministration, at 0.5mg/kg/infusion for 2 hours on an FR1 schedule, mice were reliably selfadministering cocaine at a mean dose of 12mg/kg over the 2 hour sessions (Figure 5.10). When
mice were then immediately pretreated with a subcutaneous injection of 3mg/kg U50,488 or
saline before self-administration sessions, the U50,488-treated mice increased cocaine intake
(Figure 5.10). Similarly, a pretreatment of 10µg/kg nalfurafine caused an apparent increase in
cocaine intake in the same paradigm. A 15 minute pretreatment with 3mg/kg of the antagonist
LY2444296 before the nalfurafine injection blocked this effect, suggesting that it is KORmediated (Figure 5.11). Although the nalfurafine-treated group was only statistically significant
compared to the LY/Saline control group on one day, this trend persisted over 7 consecutive days
(Figure 5.11). In the same paradigm, pretreatment with a smaller dose of 3µg/kg nalfurafine
alone had no effect on cocaine self-administration compared to saline, demonstrating a dosedependent profile of this KOR agonist (Figure 5.12).
108

Figure 5.10. Effect of U50,488 on cocaine IVSA in mice, after acquisition. Mice
intravenously self-administered 0.5mg/kg/infusion cocaine under an FR1 schedule for 2 hours
daily until acquisition was stable (<20% variation across two consecutive days) and >70% of
total nose pokes were in the active hole. Mice were injected with 3mg/kg U50,488 or saline
immediately before IVSA sessions on pretreatment days. A. Daily cocaine intake. Two-way
ANOVA (Treatment x Time), with repeated measures on Time, revealed a significant effect of
Treatment (F(1,12) = 5.84, p < 0.05) and Time (F(8,96) = 15.78, p < 0.0001) but no interaction
(F(8,96) = 1.49). Sidak’s multiple comparison test for each day revealed a significant difference
between Saline and U50,488-treated groups on Day 8 (*p < 0.05). B. Average cocaine intake
during the pretreatment days (Days 8 and 9).
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Figure 5.11. Effect of 10µg/kg nalfurafine on cocaine IVSA in mice, after acquisition. Mice
intravenously self-administered 0.5mg/kg/infusion cocaine under an FR1 schedule for 2 hours
daily until acquisition was stable (<20% variation across two consecutive days) and >70% of
total nose-pokes were in the active hole. Mice were injected with 3mg/kg LY2444296 or vehicle,
and then 15 minutes later injected with 10µg/kg nalfurafine or saline immediately before IVSA
sessions on pretreatment days. A. Daily cocaine intake. Two-way ANOVA (Overall treatment
condition x Time), with repeated measures on Time, revealed no overall effect of Treatment
(F(3,24) = 0.75), but a significant effect of both Time (F(12,288) = 7.31, p <0.0001) and
Treatment x Time Interaction (F(36,288) = 1.63, p < 0.05). Sidak’s multiple comparisons test for
each day revealed only a significant difference between Vehicle/Nalfurafine group and the
LY/Saline group on Day 11 (*p<0.05). B. Average cocaine intake during the pretreatment days.
Two-way ANOVA (LY Pretreatment x Nalfurafine Treatment) revealed no significant effect of
LY244296 pretreatment alone (F(1,24) = 1.67), or nalfurafine treatment alone (F(1,24) = 2.67),
however there was a significant interaction of LY2444296 x nalfurafine (F(1,24) = 4.71, p <
0.05). Newman-Keuls post-hoc analysis revealed a significant difference between
Vehicle/Nalfurafine and LY/Saline groups (*p < 0.05).
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Figure 5.12. Effect of 3µg/kg nalfurafine on cocaine IVSA in mice, after acquisition. Mice
intravenously self-administered 0.5mg/kg/infusion cocaine under an FR1 schedule for 2 hours
daily until acquisition was stable (<20% variation across two consecutive days) and >70% of
total nose-pokes were in the active hole. On pretreatment days (8-14), mice were injected with
3µg/kg nalfurafine or saline immediately before IVSA sessions. Two-way ANOVA (Treatment x
Time), with repeated measures on Time, showed a significant effect of Time (F(13,234) = 9.17),
but no effect of Treatment (F(1,18) = 0.194).
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5.3.3 Effect of nalfurafine on acquisition of cocaine self-administration
In an additional experiment, mice were treated with 10µg/kg nalfurafine during the initial
acquisition of cocaine self-administration. These mice immediately increased their intake of
cocaine compared to saline-treated animals (Figure 5.13). This effect appeared to be temporary
and reversible, as the nalfurafine-treated mice returned to saline-treatment levels when they
received saline injections instead (Figure 5.13).

Figure 5.13. 10µg/kg nalfurafine on acquisition of cocaine IVSA in mice. Mice were given
pretreatment injections of 10µg/kg nalfurafine or saline immediately before IVSA sessions for
Days 1-6 and Days 9 and 10. All mice were given saline injections immediately before IVSA
sessions on Days 7 and 8. IVSA sessions were 2 hours, on an FR1 schedule with
0.5mg/kg/infusion cocaine. Two-way ANOVA (Treatment x Time), with repeated measures on
Time, revealed a significant effect of Treatment (F(1,29) = 7.64, p<0.01), Time
(F(9,261(=11.42, p<0.0001), and interaction (F(9,261)=3.01, p<0.005). Sidak’s multiple
comparisons test for each day revealed significant differences between Group 1 and Group 2
(*p<0.05, **p<0.005).
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5.3.4 Discussion
In these assays, both U50,488 and nalfurafine were able to modulate cocaine-related
behaviors at doses that were not aversive and not sedative. The doses of 3µg/kg and 10µg/kg
nalfurafine, for example, were not sedative in the rotarod assay (Figure 5.4 A and B) and did not
cause aversion on their own (Figure 5.6), but were able to block cocaine-conditioned place
preference (Figure 5.9). These doses of nalfurafine also caused significant prolactin release,
demonstrating that nalfurafine still activated the KOR in mice at this dose (Figure 5.2 A and B).
The dose of 3mg/kg of U50,488 was also able to block cocaine-induced CPP without causing
aversion on its own (Figure 5.5 and Figure 5.8), suggesting that this beneficial therapeutic
window, between modulation of cocaine-related behavior and aversion, may be a property of the
KOR system in general and not unique to nalfurafine. This is in contrast to studies of the
antinociceptive and antipruritic effects of nalfurafine and other KOR agonists, but consistent
with previous CPP and self-administration studies demonstrating that anti-reward and aversive
effects of KOR agonists can be uncoupled. The mechanism of this uncoupling could be related to
different signaling mechanisms, as has been suggested for the uncoupling of therapeutic effects
and sedation, however it is also possible that both anti-reward and aversion are mediated by
dopamine inhibition downstream of the KOR and their uncoupling is a result of different
thresholds.
Interestingly, both 3mg/kg U50,488 and 10µg/kg nalfurafine had opposing effects on
cocaine-conditioned place preference and cocaine IVSA. At these doses, both compounds
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blocked cocaine CPP, but caused significant potentiation of cocaine self-administration after
mice had already acquired self-administration behavior (Figures 5.10 and 5.11). In the CPP
assay, mice received a nalfurafine pre-treatment during the cocaine conditioning sessions,
theoretically blunting the dopaminergic response to cocaine and the subsequent Pavlovian
conditioning. In the initial self-administration experiment (Figure 5.11), mice had already
learned the operant behavioral response to cocaine during the acquisition phase. When they then
received KOR agonist injections, it is possible that they increased their self-administration
behavior to overcome the blunting of the dopaminergic response to cocaine. We hypothesized
that if mice were given KOR agonist injections during the initial acquisition phase, the effect
would be similar to the CPP experiment in that the mice would not learn the operant behavioral
response to cocaine.
In contrast, we found that mice treated with nalfurafine immediately prior to these initial
sessions also increased their cocaine self-administration compared to saline-treated animals
(Figure 5.13). Previous studies of KOR agonists like U50,488 have shown a potentiation of
cocaine reward, both using CPP18 as well as IVSA, at certain doses of cocaine. 118 Additionally,
in a food vs cocaine-choice paradigm in rhesus monkeys, chronic U50,488 treatment increased
responding for cocaine over food, even as it decreased responding rates overall.119,120 This is
consistent with the idea that activation of the KOR decreases the reinforcing effects of drugs of
abuse like cocaine, and that increased self-administration behavior is observed as animals require
additional drug administration to reach the same levels of reward and dopamine release.
The divergent effects of 3mg/kg U50,488 and 10ug/kg nalfurafine in cocaine CPP and
cocaine IVSA highlight the differences between these assays. While both assays are commonly
used to measure drug reward, studies have suggested that they do not measure the same reward
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processes in the brain (reviewed in Bardo, 2000).121 Certain classes of drugs, such as the
hallucinogen lysergic acid diethylamide (LSD), cause CPP in rats but are not self-administered,
and others, such as pentobarbitol, are self-administered but do not cause CPP. Additionally,
pretreatment of animals with D2-receptor antagonists blocks the self-administration of cocaine,
but not cocaine CPP, again suggesting that these behaviors involve different mechanisms.
A lower dose of 3µg/kg nalfurafine, however, blocked cocaine place preference (Figure 5.9
B) and did not cause any measurable change in cocaine self-administration (Figure 5.12). Very
low doses of nalfurafine have also been effective in blocking alcohol intake in animal models,
especially in combination with naltrexone, a mu opioid antagonist and kappa opioid G-protein
biased partial agonist.115 While additional experiments are necessary, these preliminary data,
combined with the favorable post-marketing data from Japan, suggest that very low doses of
nalfurafine could potentially be used to block drug reward. It is also possible that very low doses
of U50,488 could have a similar effect, in light of the similar effects of 3mg/kg U50,488 and
10µg/kg nalfurafine. Overall, these data suggest that relatively low doses of potent KOR
agonists, or possibly partial agonists, may be able to successfully modulate cocaine-related
behaviors at doses that do not cause the side effects that have hampered the development of KOR
agonists previously.

117

CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS
There has been a great deal of work done over the past 50 years to investigate the effects
of KOR agonists both in human and animal models of diseases, including addictive diseases.
Here, we have added to this work with investigations of structurally-diverse KOR agonists and
their effects on different KOR signaling modalities and behaviors.
In Chapter 3, 21 structurally diverse KOR agonists were tested for their G-protein versus
b-arrestin-2 bias using cell-based functional assays. Several compounds tested had notable bias
profiles, including the relatively unbiased salvinorin compounds. The morphinan compounds
were especially G-protein biased, with the exception of nalfurafine, which was among the only
b-arrestin-biased compounds reported here or elsewhere in the literature. We found that using
heterologous cell lines for measuring G-protein activity may not accurately reflect signaling in
the disease-relevant tissue, and future studies of G-protein signaling in brain homogenate tissue
will be important for accurately profiling different KOR agonists. In particular, the ligand bias of
nalfurafine varies widely in the literature, depending on assay and cellular context, and
measurements of signaling in the relevant tissue will be important for understanding its in vivo
effects in the future.
Despite these caveats, we identified a significant correlation between in vitro b-arrestin-2
signaling, particularly the maximum efficacy in this signaling pathway, and the maximum
sedative effect of KOR agonists in mice, measured by the rotarod assay. This supports previous
studies that have suggested that arrestin recruitment is necessary for KOR-mediated sedation,
and suggests that a G-protein biased KOR agonist may be beneficial for avoiding sedative side
effects in therapeutic development. While studies in humans with non-selective G-protein biased
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KOR agonists, like nalmefene and naltrexone, support this hypothesis, a KOR-selective Gprotein biased agonist has not been tested in humans.
In Chapter 4, we investigated the effects of these diverse KOR agonists on two
additional signaling pathways – ERK1/2 and mTOR. We did not find any evidence that either
early G-protein or b-arrestin-2 signaling pathway directly or uniquely activated ERK1/2 or
mTOR, suggesting that these pathways should be studied independently in the future. Future
studies are also needed to further investigate the relationship between KOR-mediated behavior
and ERK1/2 and mTOR signaling pathways. Additionally, we compared protein-receptor
interactions at the KOR after activation by several different KOR ligands and found that ligand
bias could affect these interactions. Future studies will focus on identifying the effect of different
KOR agonists on other signaling pathways, such as 14-3-3 signaling, as well as the role of these
pathways and proteins in KOR-mediated effects in vivo.
In Chapter 5, we examined the effects of pharmacologically distinct KOR agonists on
behaviors in mice. In particular, we found that the extremely G-protein biased agonist BPHA
was still able to cause aversion, but not sedation, at high doses. We also investigated the effects
of nalfurafine – the only KOR-selective agonist to be used clinically in humans, albeit only in
Japan currently. We found that nalfurafine could block cocaine-reward without causing aversion
at very low doses (3µg/kg), and that slightly higher doses (10µg/kg) caused an increase in
cocaine intake – likely as compensation for decreasing the reinforcing effects of cocaine. Similar
results with a low dose of 3mg/kg U50,488 suggests that decreasing the reinforcing effects of
cocaine may be a feature of KOR activation, and not unique to nalfurafine. These data suggest
that a very low dose of a potent KOR agonist, or perhaps a partial agonist, could be effective for
modulating cocaine reward without causing aversive or sedative side effects. Additional
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experiments in preclinical models, and likely humans, are needed to determine how to translate
this effect into a desirable therapeutic response.
KOR agonists have been shown previously to both block and potentiate the rewarding
and reinforcing effects of drugs of abuse like cocaine. It is apparent that the KOR system is
involved in drug-related behaviors and reward, however the side effects such as sedation,
aversion and hallucinations have prevented KOR agonists from being tested in humans for this
indication. While the psychotomimetic effects of KOR agonists can’t be tested in animal models,
our data suggest that some of these side effects could be avoided by very low doses of KOR
agonists, or agonists with specific pharmacological profiles, while still affecting the rewarding
properties of cocaine. It is also likely that future studies investigating the effects of other
signaling pathways, such as ERK1/2, mTOR or 14-3-3, could help to further narrow down a
pharmacological profile for a KOR agonist with fewer side effects. These data also support the
idea, first proposed by the Kreek lab, that a KOR-selective partial agonist could be used for the
treatment of cocaine addiction. The development of novel KOR agonists, including partial
agonists, agonists with unique signaling profiles and very potent agonists, will be essential for
testing these hypotheses in the future.
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